Clinical Investigation  Plan Cover Page  
NCT Number: [ADDRESS_358234] Occluder II Additional Sizes (ADO II AS) Clinical Study  
Study Document No: SJM -CIP-[ZIP_CODE]  
Version D 
Date: 02-AUG-[ADDRESS_358235] North  
Plymouth, MN [ZIP_CODE] [LOCATION_003]  
 Study Document No: SJM-CIP-[ZIP_CODE]   Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page [ADDRESS_358236] Occluder II Additional Sizes (ADO II AS) Clinical Study  
CRD_ 805 
Study Document No: SJM-CIP-[ZIP_CODE]  
Version D 
Date:  [ADDRESS_358237]  2018  
Clinical Investigation Plan (CIP)  
 
 
 
Sponsor  St. Jude Medical, Inc.  
 Global Clinical Affairs  
 [ADDRESS_358238].  
 Los Angeles, CA [ZIP_CODE]  
 
  
 Study Document No: SJM-CIP-[ZIP_CODE]   Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page 2 of 51 
Table of Contents  
 
1 Introduction  ................................ ................................ ................................ ................................ ...............  5 
1.1 Continued Access Protocol (CAP) Enrollment  ................................ ................................ .................  5 
1.2 Scope and Description of CAP Enrollments  ................................ ................................ .....................  5 
2 Background and justification for clinical investigation  ................................ ................................ ...............  5 
2.1 Disease to be treated  ................................ ................................ ................................ .......................  5 
2.2 Current Treatment Options  ................................ ................................ ................................ ...............  6 
2.3 AMPLATZER PDA Occluder  ................................ ................................ ................................ ............  7 
2.4 Study Rationale (IDE and CAP)  ................................ ................................ ................................ ....... 8 
2.4.1  Pi[INVESTIGATOR_294193] ................................ ................................ ................................ ....................  8 
2.4.2  CAP Rationale  ................................ ................................ ................................ ..............................  8 
3 Device(s) under investigation  ................................ ................................ ................................ ....................  9 
3.1 Identification and description of the devices under investigation  ................................ .....................  9 
3.1.1  Identification  ................................ ................................ ................................ ................................ . 9 
3.1.2  Device Description and Intended Indications for Use  ................................ ................................  10 
3.1.3  Device handling and storage  ................................ ................................ ................................ ...... 10 
3.2 Devices accountability  ................................ ................................ ................................ ....................  10 
4 Clinical Investigation Design  ................................ ................................ ................................ ...................  11 
4.1 Clinical Investigation Design for Pi[INVESTIGATOR_170822]  ................................ ................................ ... 11 
4.2 Clinical Investigation Design for CAP Subjects  ................................ ................................ ..............  11 
4.3 Objective  ................................ ................................ ................................ ................................ .........  11 
4.4 Endpoints  ................................ ................................ ................................ ................................ ........  11 
4.4.1  Primary Endpoints (IDE and CAP)  ................................ ................................ .............................  11 
4.4.2  Secondary Endpoint (IDE and CAP)  ................................ ................................ ..........................  12 
4.4.3  Descriptive Endpoints and Additional Data for Pi[INVESTIGATOR_170822]  ................................ .........  12 
4.4.4  Descriptive Endpoints and Additional D ata for CAP Subjects  ................................ ...................  12 
4.5 Study Population  ................................ ................................ ................................ ............................  13 
4.5.1  Inclusion Criteria  ................................ ................................ ................................ .........................  13 
4.5.2 Exclusion Criteria  ................................ ................................ ................................ ........................  13 
5 Procedures  ................................ ................................ ................................ ................................ ..............  13 
5.1 Informed Consent Process  ................................ ................................ ................................ .............  14 
5.1.1  Special circumstances for informed consent  ................................ ................................ ..............  14 
5.2 Point of Enrollment  ................................ ................................ ................................ .........................  14 
5.3 Scheduled Procedures  ................................ ................................ ................................ ...................  15 
5.3.1  Screening and Baseline for Pi[INVESTIGATOR_294194]  ................................ ................................ ....... 15 
5.3.2  Screening and Baseline for CAP subjects ................................ ................................ ..................  15 
5.3.3  Implant/Procedure  ................................ ................................ ................................ ......................  [ADDRESS_358239] Withdrawal  ................................ ................................ ................................ .........................  22 
5.8 Requirements for Clinical Laboratories  ................................ ................................ ..........................  23 
5.9 Study Committees  ................................ ................................ ................................ ..........................  23 
 Study Document No: SJM-CIP-[ZIP_CODE]   Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page 3 of 51 
5.9.1  Publication Committee ................................ ................................ ................................ ................  23 
5.9.2  Clinical Events Committee (CEC)  ................................ ................................ ..............................  23 
6 Statistical Considerations  ................................ ................................ ................................ ........................  24 
6.1 Endpoints  ................................ ................................ ................................ ................................ ........  24 
6.1.1  Primary Safety Endpoint (IDE and CAP)  ................................ ................................ ....................  24 
6.1.2  Primary Effectiveness Endpoint (IDE and CAP)  ................................ ................................ ........  24 
6.1.3  Secondary Endpoint (IDE and CAP)  ................................ ................................ ..........................  [ADDRESS_358240]  ................................ ................................ .........................  33 
8.2.3  Complaints  ................................ ................................ ................................ ................................ .. 33 
8.3 Source r ecords  ................................ ................................ ................................ ...............................  33 
8.4 Records retention  ................................ ................................ ................................ ...........................  33 
9 Clinical Data Handling  ................................ ................................ ................................ .............................  33 
9.1 Protection of Personally Identifiable Information  ................................ ................................ ............  34 
9.2 Data Management Plan  ................................ ................................ ................................ ..................  34 
9.3 Document and Data Control  ................................ ................................ ................................ ...........  34 
9.3.1  Traceability of Documents and Data  ................................ ................................ ..........................  34 
9.3.2  Recording Data  ................................ ................................ ................................ ...........................  34 
10 Monitoring  ................................ ................................ ................................ ................................ ...........  34 
11 Compliance Statement  ................................ ................................ ................................ .......................  34 
11.1  Statement of Compliance  ................................ ................................ ................................ ...............  34 
11.2  Quality Assurance audits and Regulatory Inspections  ................................ ................................ ... 35 
11.3  Repeated and Serious Non -Compliance  ................................ ................................ ........................  35 
12 Suspension or premature termination of the clinical inv estigation  ................................ .....................  35 
13 Clinical Investigation Conclusion  ................................ ................................ ................................ ........  36 
14 Publication Policy  ................................ ................................ ................................ ...............................  36 
 Study Document No: SJM-CIP-[ZIP_CODE]   Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page 4 of 51 
15 Reporting Results on ClincalTrials.gov Website  ................................ ................................ ................  36 
Appendix A: CIP Revisions  ................................ ................................ ................................ ............................  37 
Appendix B: Definitions  ................................ ................................ ................................ ................................ .. 39 
Non-study Specific Definitions  ................................ ................................ ................................ ....................  39 
Study Specific Definitions  ................................ ................................ ................................ ...........................  40 
Appendix C: Labels  ................................ ................................ ................................ ................................ ........  42 
Appendix D: Bibliography  ................................ ................................ ................................ ...............................  43 
Appe ndix E: American Heart Association Recommendations for Prophylaxis  ................................ ..............  45 
Appendix F: Transthoracic Echocardiography (TTE) Protocol  ................................ ................................ ....... 47 
Appendix G: Case Report Forms  ................................ ................................ ................................ ...................  50 
Appendix H: Template Informed Consent Form  ................................ ................................ .............................  51 
 
  
 Study Document No: SJM-CIP-[ZIP_CODE]   Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page 5 of 51 
1 Introduction  
This document is a clinical investigation plan (CIP) for the AMPLATZER Duct Occluder II® Additional Sizes 
(ADO II AS) clinical investigation. This clinical investigation is intended to demonstrate the safety and 
effectiveness of St. Jude Medi cal’s ADO II AS  in subject s with a patent ductus arteriosus  (PDA).  This clinical 
investigation will be conducted under an investigational device exemption (IDE) and is intended to support 
market approval of the ADO II AS  device in the [LOCATION_002] and other countries. T his clinical investigation 
is sponsored by [CONTACT_99894]. Jude Medical  (SJM) . 
 
This clinical investigation will be conducted in accordance with this CIP. All parties involved in the conduct 
of the clinical investigation will be qualified by [CONTACT_8640], training, or ex perience to perform their tasks and 
this training will be documented appropriately.  
 
1.1 Continued Access Protocol (CAP)  Enrollment  
Protocol revision C  allows for additional subject enrollment in the ADO II AS study , with additional 
prospective collection of safety and effectiveness data on the ADO II AS device upon completion of 
enrollment of the pi[INVESTIGATOR_294195]-market approval ( PMA ) application  is being prepared and 
under FDA review.   
1.2 Scope and Description of CAP  Enrollments  
This revision to the protocol provides additional language within Sections 4, 5, and 6 , which describe 
procedural details applicable to CAP subjects enrolled under the revised protocol. Sections  pertaining only 
to CAP subjects are organized as sub -sections of their corresponding protocol section. These sub -sections 
are labeled ‘for CAP Subjects’ and are underlined for identification. For these subjects, the content o f these 
sub-sections replaces the corresponding cont ent of the associated protocol section. If sections of this 
protocol are not accompanied by a section specified for CAP subjects, then the original IDE section will be 
followed for all subjects.  
 
Subjects  previously enrolled in the IDE will not be affected by [CONTACT_294229][INVESTIGATOR_294196] . 
2 Background  and justification  for clinical  investigation  
2.1 Disease to be treated  
In the fetus, 85% of the blood by[CONTACT_294230].  The blood flows from the right ventricular 
outflow tract through the ductus arteriosus to the aorta.  At birth, the increase in oxygen tension leads to 
inhibition of local prostaglandins and causes functional closure of the du ctus, followed by [CONTACT_294231].  
A patent ductus arteriosus (PDA) is a persistence of the fetal connection (ductus arteriosus) between the 
aorta and pulmonary artery after birth, resulting in a persistent left -to-right shunt.  PDA is the most common 
cong enital heart lesion in newborns and accounts for approximately 5 to 10% of all congenital heart defects. 
The incidence of a PDA is approximately 1 in 2,000 term newborns and this incidence increases to >50% in 
premature babies, and >80% in severely prematu re low birth weight infants (<1200 gm) [ 1]. PDA is more 
common ly seen  in female infants, with a female -to-male ratio of 2:1 for PDA [ 2]. 
 
Typi[INVESTIGATOR_294197] 10 -18 hours of life, and anatomically, it is generally closed within six 
weeks [ 3]. PDA anatomy varies considerably both in diameter, length and configuration.  Krichenko et al 
 Study Document No: SJM-CIP-[ZIP_CODE]   Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page 6 of 51 
provided angiographic classification of the different PDA configurations labeled as A -type through E -type, 
which recently has been expanded by [CONTACT_294232] a l [4] to also include the tubular and longer F -type 
configuration commonly seen in premature born infants [ 5]. The PDA diameter refers to its narrowest 
segment, which is smaller than 4 mm in 78% of cases [ 6]. 
 
While this lesion may spontaneously resolve in some neonate s, persistence, particularly in premature 
infants is a major health concern. The presence of a hemodynamically significant PDA in premature infants 
has been associated with an increased risk of developi[INVESTIGATOR_294198], chronic respi[INVESTIGATOR_23697], pulmonary hemorrhage, intraventricular hemorrhage, and death [ 1, 7]. Should a baby [CONTACT_294233] a significant PDA, this lesion can result in continued morbidity during infancy, which 
includes failure to thrive, chronic respi[INVESTIGATOR_294199], and repeated hospi[INVESTIGATOR_614].  
 
Closure of PDA is indicated to restore hemodynamic status and to prevent congestive heart failure, 
pulmonary vascular disease, and , in the long -term, bacterial endocarditi s [8]. The risk of endocarditis with 
small  residual shunts remains unknown , although continued bacterial endocarditis prophylaxis is generally 
advocated as long as flow persists or a murmur can be auscultated [ 9]. 
2.[ADDRESS_358241] of care for a persistent patent ductus arteriosus  (PDA)  includes the following two 
treatment options:  surgical ligation or closure with alternative devices.  
Surgical Ligation  
PDA was the first congenital cardiac heart disease to be conquered by [CONTACT_14085].  The first surgical ligation 
of a PDA was performed by [CONTACT_294234] 1939 [ 10]. Surgical ligation or ligation and division were 
the standard of care for persistent PDA until the advent of transcatheter closure.  Today surgery remains the 
standard of care for PDA closure in preemies a nd infants with large hemodynamically significant PDAs.  
Although the standard of care, surgical ligation has been associated with the potential  risk for significant 
procedural complications (pneumothorax, hypothermia, bleeding, phrenic nerve palsy, chyloth orax, wound 
infection, vocal cord paralysis, and thoracic scoliosis [ 1, 7, 11, 12]), significant post -procedural clinical 
decline known as post -ligation syndrome [13], and poor long -term outcomes including neuro -developmental 
delay, retinopathy of prematurity and chronic lung diseas e (bronchopulmonary dysplasia) [ 11, 12]. Because 
a growing body of literature has suggested that surgical ligation of PDA in premature neonates may actually 
result in worse outcomes than no treatment at all a trend of permissive conservative observation of this 
lesion  has developed, reserving surgery for o nly the most severe cases. Unfortunately, recent data 
suggests that this approach is associated with an increased risk for the development of chronic lung 
disease and death [15]. 
Transcatheter device closure  
The first interventional closure of a PDA was pe rformed by [CONTACT_294235] 1967 [1 4] and has emerged as the 
gold standard for treatment of this lesion in larger infants, children and adults [ 7]. Historically, transcatheter 
closure of a PDA has not been performed in infants and premature neonates for a vari ety of reasons 
including: fear of patient fragility; concerns regarding vascular access and arterial injury; unknown effects of 
intravenous contrast media; concerns regarding catheter manipulation; and most importantly, absence of a 
suitable PDA closure de vice. Recently, a growing body of clinical evidence has emerged suggesting that 
transcatheter closure of PDA can be performed safely and effectively in selected infants and premature 
newborns. The ADO II AS device has the ideal characteristics (size, shape , delivery system) for this unique 
population but its lack of availability in the [LOCATION_003] has limited wide spread adaptation of this procedure.   
 Study Document No: SJM-CIP-[ZIP_CODE]   Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page [ADDRESS_358242] Occluder II, included 192 subjects who were greater than six months in age and 
greater than six kilograms in weight  [16]. A total of 178/192 (92.7%) subjects were successfully implanted 
with the AMPLATZER Duct Occluder  II. There were 3 reports of device or procedure -related Serious 
Adverse Event s (SAE s) within 180 days of implant (3/192; 1.56%).  Of the successful implants, c omplete 
closure of the ductus was reported in 98.19% of subjects at the six -month follow -up interval.  The 
AMPLATZER Duct Occluder II Additional Sizes device was  designed as a line extension to ADO II to allow 
closure of smaller sizes of a PDA.  
Key differences between the ADO II and ADO II AS device are the size and shape. The ADO II device has 
a narrow wai st with larger retention discs, while the ADO II AS device has a cylindrical waist with lower 
profile retention discs that are minimally larger than the waist and resulting in a nearly isodiametric device. 
The ADO II device is larger and designed to treat a PDA with a diameter ranging between 2.5 and 5.5 mm 
and a length between 5 and 12 mm.  The ADO II AS is designed to treat a PDA with a diameter ≤ 4.0 mm 
and a length ≥ 3.[ADDRESS_358243] from a 4 French (4F) delivery catheter either by [CONTACT_294236]. 
The central waist is designed to fill the ductal lumen, and the reten tion discs are designed to deploy in the 
pulmonary and the aortic end of the ductus arteriosus. The ADO II AS comes pre -attached to a delivery 
cable. The delivery cable’s distal tip is extremely flexible and has angiographically visible properties, which 
helps to achieve precise placement of the proximal disc during device placement and unscrewing. 
TorqueVue Low Profile Delivery Catheter has 4F outer diameter compatible with all 9 ADO II AS occluders.  
The ADO  II AS device has a design well suited to the ana tomy of the infant and neonatal PDA which tends 
to be more tubular (so -called F -type) than the PDA of older children and adults which tends to be conical in 
shape [1 7]. Importantly, the short lengths (2 and 4 mm) of the ADO  II AS may greatly reduce the ris k of 
descending aortic or left pulmonary arterial stenosis that can be caused by [CONTACT_294237]. The ADO II AS device has a tubular shape with low profile discs, 
which makes it suitable for insertion in to a tubular PDA from either an ante rograde or a retrograde 
approach, facilitating successful implant and making it possible to avoid access via the femoral artery 
(important in premature infants). Finally, the softer delivery wire and low profile  system (4 F) used for the 
ADO II AS device are ideal for the small delicate vasculature of small infants.  Procedural related 
complications associated with implanting the device in small infants may be minimized by [CONTACT_294238].  
 
Although the device is recommended for ductal diameters up to [ADDRESS_358244] diameter available 
is 5 mm with the retention discs only 1.5 mm larger. This leaves very little extra anchoring with this device 
compared to either the ADO or the ADO II, and therefore, the maximum diameter for deployment should be 
less than or equal to 4 mm. Tubular PDA’s in young infants may stretch more easily. The small, flexib le 
retention discs provide minimal anchoring support, meaning that the device relies heavily on constraint of 
the central portion for stable positioning. Careful device diameter sizing is required in larger ductal 
diameters to avoid embolization. The devic e may be implanted in ducts that are longer in length than the 
 Study Document No: SJM-CIP-[ZIP_CODE]   Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page 8 of 51 
length of the device, as long as the selected device diameter satisfies the specified di ameter within the 
sizing chart.  
2.4 Study Rationale  (IDE and CAP)  
2.4.1  Pi[INVESTIGATOR_294200] s investigation is to offer patients a safe and effective device for closure of a small PDA 
(≤ 4 mm diameter) with an FDA approved device.  Current treatment for smaller PDAs includes off label use 
of devices.  Major drawbacks of current devices in terms of this unique population include: device length (too 
long, placing the left pulmonary artery and descending aorta at risk for obstruction), device shape (large 
retention disks placing the left pulmonary artery and descending aorta at risk for obstruction), a nd stiffness 
of delivery systems. Currently there is no FDA approved device for PDA closure in patients <5 kg or <6 
months of age, which encompasses virtually all infants, neonates and premature neonates.  
 
2.4.2  CAP Rationale  
The rationale for the CAP is to allow current IDE study implanters to maintain their technical proficiency in 
ADO II AS  device implantation  and to allow additional  implanters to gain experience with the device  after 
enrollment completion in the pi[INVESTIGATOR_294201] -market approval (PMA) application for the 
ADO II AS device is being prepared and is under FDA review . Data from the CAP may be used to support 
post approval requirements  for the ADO II AS occluder .  
 
  
 Study Document No: SJM-CIP-[ZIP_CODE]   Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page 9 of 51 
3 Device(s) under investigation  
3.1 Identification and description of the devices under investigation  
3.1.1  Identification  
Figure 1: ADO II AS Device  
 
Table 1: Identification of Devices under Investigation  
Device Name  [CONTACT_26159]/Type  A 
mm (in)  B 
mm (in) C 
mm (in)  Investigational 
or Market 
Released  
ADO II AS Occluder  9- PDA2ASIDE -03-02 4.00 (0.157)  3.00 (0.118)  2.00 (0.079)  Investigational  
ADO II AS Occluder  9- PDA2ASIDE -03-04 4.00 (0.157)  3.00 (0.118)  4.00 (0.157)  Investigational  
ADO II AS Occluder  9- PDA2ASIDE -03-06 4.00 (0.157)  3.00 (0.118)  6.00 (0.236)  Investigational  
ADO II AS Occluder  9- PDA2ASIDE -04-02 5.25 (0.207)  4.00 (0.157)  2.00 (0.079)  Investigational  
ADO II AS Occluder  9- PDA2ASIDE -04-04 5.25 (0.207)  4.00 (0.157)  4.00 (0.157)  Investigational  
ADO II AS Occluder  9- PDA2ASIDE -04-06 5.25 (0.207)  4.00 (0.157)  6.00 (0.236)  Investigational  
ADO II AS Occluder  9- PDA2ASIDE -05-02 6.50 (0.256)  5.00 (0.197)  2.00 (0.079)  Investigational  
ADO II AS Occluder  9- PDA2ASIDE -05-04 6.50 (0.256)  5.00 (0.197)  4.00 (0.157)  Investigational  
ADO II AS Occluder  9- PDA2ASIDE -05-06 6.50 (0.256)  5.00 (0.197)  6.00 (0.236)  Investigational  
AMPLATZER™ 
TorqVue™ LP 
Catheter  9-TVLPC4F90/080  Not  
Applicable  Not 
Applicable  Not  
Applicable  Market Released  
 
Table 2: Device Sizing Chart for subjects >2 Kg  
Measured Ductus  
Diameter mm (in)  Minimal Measured Ductus Length mm (in)  
3–4 (0.118 –0.157)  4.1–6 (0.161 –0.236)  6.1–8 (0.240 –0.315)  
≤2 (≤0.079)  9-PDA2ASIDE -03-02 9- PDA2ASIDE -03-04 9- PDA2ASIDE -03-06 
2.1–3 (0.083 –0.118)  9- PDA2ASIDE -04-02 9- PDA2ASIDE -04-04 9- PDA2ASIDE -04-06 
3.1–4 (0.122 –0.157)  9- PDA2ASIDE -05-02 9- PDA2ASIDE -05-04 9- PDA2ASIDE -05-06 
  

 Study Document No: SJM-CIP-[ZIP_CODE]   Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page 10 of 51 
Table 3: Device Sizing Chart for subjects ≤2 Kg  
Measured Ductus  
Diameter mm (in)  Minimal Measured Ductus Length mm (in)  
3–6 (0.118 –0.236) ≥6.1 (≥0.240) 
≤1.5 (<0.059) 9-PDA2ASIDE -03-02 9- PDA2ASIDE -03-04 
1.6–2.5 (0.063 –0.098)  9- PDA2ASIDE -04-02 9- PDA2ASIDE -04-04 
2.6–4 (0.102 –0.157)  9- PDA2ASIDE -05-[ADDRESS_358245] Occluder II Additional Sizes (ADO II AS)  is a percutaneous transcatheter occlusion 
device intended for the non -surgical closure of PDAs. The AMPLATZER TorqVue LP Delivery System is 
intended to facilitate the attachment, loading, delivery and deployment of the ADO II AS.  
The ADO II AS  is a self -expandable Nitinol mesh occlusion device for the occlusion of patent ductus 
arteriosus (PDA). The device configuration is a central waist with two retention disks. The central waist is 
designed to fill the defect and the two retention disks are designed to be deployed on the arterial and 
venous sides of the defect. Because of the isodiametric design of the device it may be implanted in ducts 
longer than the device as long as the di ameter of the device is sufficiently large to constrain the device 
within the PDA. Devices are available in three lengths to accommodate various lengths of PDA. The ADO II 
AS has a screw attachment for a delivery wire and radiopaque marker bands at both ends.  
The AMPLATZER TorqVue LP Catheter consists of a delivery catheter,  Touhy -Borst hemostasis valve, 
loading device, and a self-sealing hemostasis valve. The delivery catheter  was designed to facilitate 
attachment, loading, delivery and deployment of AMPLATZER device s pre -loaded onto a delivery wire . The 
TorqVue LP Catheter  is not i nvestigational . 
3.1.[ADDRESS_358246] maintain records of  the date of receipt, the 
identification of each investigational device (batch number, serial number or unique code), the subject 
identification, the date of use, the expi[INVESTIGATOR_1516] d ate and final disposition.  
 
Storage locations for the devices at investigational sites will be locked with access restricted only to 
investigators and authorized personnel.  
 
Sponsor  must also maintain device accountability documenting all shipments and re turns o f investigational 
devices.  
 Study Document No: SJM-CIP-[ZIP_CODE]   Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page 11 of 51 
4 Clinical Investigation Design  
4.1 Clinical Investigation Design  for Pi[INVESTIGATOR_294202] a single arm, prospectiv e, multicenter, non -randomized clinical investigation 
designed to characterize  the saf ety and effectiveness of the ADO II AS device in patient s with a patent 
ductus arteriosus (PDA). The study will be conducted at up to 10 centers within the [LOCATION_002].  
 
Subjects will be implanted with the ADO II AS device using a transcatheter femoral v essel approach under 
fluoroscopic and  echocardiographic guidance. Clinical follow -up will be performed at 1 month, 6 months, 12 
months , 24 months, and 36 months  following the implant procedure. A pre-market approval (PMA) 
application will be submitted afte r [ADDRESS_358247] implant attempt. A 
minimum of 15 subjects will be enrolled wit h a weight ≤ 2 kg. In the event  there is difficulty in enrolling 15 
subjects with a weight of < 2 kg, a PMA application will be submitted af ter 25 subjects with weight > [ADDRESS_358248] reached 6 months of follow -up. An additional submission will be done when  15 subjects with a weight 
of < [ADDRESS_358249] -
approval requirements.  
 
The clinical investigation will be conducted at approximately 10 centers in the [LOCATION_002] .  
Up to f ifty (50) subjects will be enrolled in the clinical investigation . No site may enroll more than 30 % of 
total subjects.  
 
The expected duration of enrollment is approximately [ADDRESS_358250] s with  a patent ductus arteriosus  (PDA) . 
4.4 Endpoints  
The s afety and effectiveness endpoints of the clinical investigation are as follows:  
4.4.1  Primary Endpoint s (IDE and CAP)  
Primary Safety Endpoint:  
The primary safety endpoint is the rate of major complications through  180 days after an attempted ADO II 
AS device im plant  (refer to Appendix B for definition s). 
 
 
 
 
 Study Document No: SJM-CIP-[ZIP_CODE]   Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page 12 of 51 
Primary Effectiveness Endpoint:  
The primary effectiveness endpoint is the rate of effective  closure of the ductus arteriosus among patients 
with a successful ADO II AS implant as assessed by [CONTACT_294239] a Grade 0 or Grade 1 shunt, as 
defined below, at the six -month follow -up by [CONTACT_294240]  (TTE) . 
 
PDA shunt definition:  
• Grade 0 —none ; 
• Grade 1 —trivial (narrow jet adjacent to the  device via  the PDA) . Note: the presence of flow via 
existing or newly formed aortopulmonary collaterals should not be considered as representing a 
shunt via the PDA.  (see references in Appendix F  by [CONTACT_294241])  
• Grade 2 —mild (broader jet filling proximal left pulmonary artery branch and extending to main 
pulmonary artery) ; 
• Grade 3 /4—moderate  to severe  (wide jet filling the main pulmonary artery and extending to 
pulmonary valve  or distal pulmonary artery branches, which also may be accompanied with the 
presence of flow reversal in the abdominal aortic Doppler pattern during diastole)  
4.4.2  Secondary Endpoint  (IDE and CAP)  
The secondary endpoint is the rate of significant obstruction of the pulmonary artery or aorta through the 6 -
month follow -up visit  per the following definitions:  
1. Significant obstruction of the left pulmonary artery is defined as less than 30% flow to the left lung 
by [CONTACT_294242] a peak instantaneous gradient in left pulmonary artery ≥35 mmHg by 
[CONTACT_294243].  OR 
2. Significant obstruction of the aorta is defined as a gradient of ≥20 mmHg in the aortic isthmus by 
[CONTACT_294244] a mean gradient ≥20 mmHg in the aortic isthmus by 
[CONTACT_294245].  
4.4.3  Descriptive Endpoint s and Additional Data  for Pi[INVESTIGATOR_294203] .   
• Implant success  
• PDA shunt grade status at each follow -up visit  
• Gradient measurements of the pulmonary artery and aorta at each follow -up visit  
• Major and Minor Complications  
• Death  
• Additional data: demographics and baseline characteristics, procedure inform ation , and left 
ventricular function and dimensions, pulmonic and tricuspid regurgitation , adverse events, 
withdrawal and protocol deviations  will also be summarized  at each follow -up visit .   
4.4.4  Descriptive Endpoints and Additional Data for CAP  Subjects  
Descriptive endpoints will be  reported using summary statistics .   
• Implant success  
• Major and Minor Complications  
• Death  
• Additional data:  
Demographics and baseline characteristics , procedure information , left ventricular function and 
dimensions and pulmonic and tricuspid regurgitation at 6 months , and adverse events, withdrawal 
and protocol deviations  will also be summarized  at each follow -up visit .   
 Study Document No: SJM-CIP-[ZIP_CODE]   Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page [ADDRESS_358251] meet all of the following inclusion criteria:  
• Diagnosis of a PDA  
• PDA ≤ 4mm in diameter  
• PDA ≥ 3mm in length  
• Subject (or legally authorized representative) is willing to comply with all pre -procedure , post -
procedure , and follow -up testing requirements and provides consent to participate in the clinical 
study * 
 
* This study is enrolling children an d all local laws and governing IRB requirements will be followed for 
obtaining informed c onsent.  
4.5.[ADDRESS_358252] be excluded from the clinical investigation:  
• Weight < 700 grams at time of th e procedure  
• Age < 3 days at time of procedure  
• Coarctation of the aorta  
• Left pulmonary artery stenosis  
• Cardiac output that is dependent on right to left shunt through the PDA due to pulmonary 
hypertension  
• Intracardiac thrombus  
• Active infection requiring treatment at the time of implant  
• Female subjects of child bearing potential  are either pregnant or desire to become pregnant within 
six months post implant  
• Other disease process likely to limit survival to less than six (6) months  
• Participating in another study for an investigational drug and/or device that may clinically interfere 
with this study's endpoints  
[ADDRESS_358253] be received prior to initiating study procedures.  
 
Enrolled subjects (as defined in section 5. 2) will undergo a PDA closure procedure with the ADO II AS 
device . Post-procedure, the subject will  have follow -up visits at [ADDRESS_358254] completed the follow -up requirements of this clinical investiga tion. The Principal I nvestigator should 
arrange for appropriate care of subjects following study completion.   
 
The following sections provide a detailed description of procedures required by [CONTACT_20812].  
 Study Document No: SJM-CIP-[ZIP_CODE]   Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page 14 of 51 
5.1 Informed Consent Process  
The P rincipal Investigator or his/her authorized designee will conduct the Informe d Consent Process , as 
required by [CONTACT_26137]’s IRB. This process will include a ver bal discussion with 
the patient and/or patient’s  legally authorized representative on all aspects of the clinical investigation  that 
are relevant to the patient’s  decision to participate , such as details of clinical investigation procedures, 
anticipated benefits, and potential risks of clinical investigation participation . During the discussion, the 
Principal Investigator [INVESTIGATOR_022]/her authorized desig nee will avoid any improper i nfluence on the patient’s  
legally authorized representative and will respect patient’s  legal rights. The patient ’s legally authorized 
representative shall be provided with the informed consent form written in a language that i s 
understandable to the subject’s legally authorized representative and has been ap proved by [CONTACT_16018]’s 
IRB. The patient’s  legally authorized representative shall have adequate  time to review , ask questions  and 
consider participation.  
 
If the patient’s  legally authorized representative agrees  to participate , the Informed C onsent form must be 
signed and dated by [CONTACT_102]’s  legally authorized representative and by [CONTACT_98902].  
The signe d original Informed Consent will be filed in the subject’s hospi[INVESTIGATOR_26107], and a copy  
will be provided to the subject.  
 
The Principal I nvestigator or his/her authorized designee will  document the informed consent process in the 
subject’s hospi [INVESTIGATOR_3491]/or research charts. The date of signatur e will be entered on an appropriate Case 
Report Form ( CRF).  
 
Failure to obtain informed consent from a subject prior to clinical investigation  enrollment should be 
reported to Sponsor  within 5 working days an d to the reviewing center’s IRB according to  the IRB ’s/ EC’s 
reporting requirements.  
 
The Principal I nvestigator or his/her authorized designee will  inform the subject of any important new 
information about the clinical investigation.  
5.1.[ADDRESS_358255] be obtained 
using the IRB  approved informed consent in accor dance with IRB  requirements.  
 
If the patient  is under the age of 18, the l egally authorized representative will represent the patient during 
the informed consent process, which will be performed according to the requirements in section  5.1. The 
patient  under the age of 18 will also be informed about the clinical investigation wi thin his/her ability to 
understand.  Per state, local, and/or IRB requirements, processes will be followed and documented to collect 
assent for minor children.  
5.2 Point of Enrollment  
A patient  is considered enrolled in the clinical investigation from the momen t the patient’s  legally authorized 
representative  has provided a written Patient Informed Consent, has been confirmed  to meet all inclusion 
criteria, meets none of the exclusion criteria, and the TorqVue™ LP Catheter ( 9-TVLPC4F90/080 ) is 
inserted into the vasculature of the subject.  An intra -procedural  echocardiogram  or angiogram  must be 
performed to confirm the sizing inclusion criteria of the PDA length (≥ 3 mm) and PDA diameter (≤ 4 mm) 
prior to inserting the delivery catheter into the vasculature.  
 
 Study Document No: SJM-CIP-[ZIP_CODE]   Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page [ADDRESS_358256] enrollment information (name [CONTACT_294270], date of consent and Inclusion/exclusion information) in the hospi[INVESTIGATOR_294204] a time ly manner.  
 
Notification of enrollment to the Sponsor is considered to have occurred when the Procedure  CRF has been 
received by [CONTACT_1034].  
5.[ADDRESS_358257] review 
or prospective tests and evaluations : 
• Demographics - including subject’s age and gender  
• Physical examination -  
o include su bject’s weight, upper and lower extremity blood pressure measurements taken 
during visit , heart murmur evaluation , and assessment of femoral pulses.  
• Medical History -  
o indicate subject’s risk factors, relevant co -morbidities, neonatal ICU status, previous cardiac 
procedures  
• Cardiovascular History (most recent information  closest to baseline visit)  
• Pregnancy test (required only for females of ch ild bearing potential)  
• Transthoracic echo (TTE) - within 14 days prior to the device implant procedure  
o PDA measure ments, left ventricular function and dimensions (area and length), pulmonary 
and aortic flow and dimensions, and pulmonic and tricuspid valve regurgitation  
• Electrocardiogram (ECG)  
• Chest X -ray (CXR) – Anteroposterior view  
 
Baseline assessments must be collected within [ADDRESS_358258] the 
screening failure in th e hospi[INVESTIGATOR_294205] a screening log as required.  
5.3.2  Screening and Baseline for CAP  subjects  
Potential subjects  presenting at the investigational sites will be fully informed about the clinical investigation, 
following the established Informed Consent process described in section 5.1. Once a duly dated and signed 
Informed Consent Form is obtained, the study -specifi c screening procedures and assessments may begin.   
 Study Document No: SJM-CIP-[ZIP_CODE]   Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page [ADDRESS_358259] review 
or prospective tests and evaluations:  
• Demographics - including subject’s age and gender  
• Physical exami nation -  
o include su bject’s weight, heart murmur evaluation , and assessment of femoral pulses.  
• Medical History -  
o indicate subject’s risk factors, relevant co -morbidities, neonatal ICU status, previous cardiac 
procedures  
• Cardiovascular History (most recent information  closest to baseline visit)  
• Pregnancy test (required only for females of child bearing potential)  
• Transthoracic echo (TTE) - within 14 days prior to the device implant procedure  
o PDA measure ments, left ventricular function and dimensions (area an d length), pulmonary 
and aortic flow and dimensions, and pulmonic and tricuspid valve regurgitation  
• Electrocardiogram (ECG)  
• Chest X -ray (CXR) – Anteroposterior view  
 
 
Baseline assessments must be collected within [ADDRESS_358260] the 
screening failure in the hospi[INVESTIGATOR_294205] a screening log as required.  
 
5.3.3  Implant/Procedure  
The ADO  II AS device is implanted either transvenously or transarterially  via the femoral vessels . To 
minimize complications in small infants (≤ 2 kg) it is recommended to utilize the anterograde transvenous 
approach via the femoral vein as the preferred approach.  The use of invasive hemodynamic measurements 
and angiograms are not required in this study to minimize complications, and instead whenever possible 
hemodynamic assessments and visualization of the anatomy may be performed using intra -operative 
echocardiography.  The operator must complete an int ra-procedural echocardiogram or angiogram to 
confirm the sizing inclusion criteria of the PDA length (≥ 3 mm) and PDA diameter (≤ 4 mm) prior to 
inserting the TorqVue™ LP Catheter into vasculatu re. 
 
Proper sizing of the ADO II AS device is important in all subjects to reduce risk of complications.  Refer to 
the Instructions for Use (IFU) in Appendix C: Product Labeling  for important instructions regarding device 
sizing.   
 
The recommended use of H eparin is co nsidered optional, and not required if the subject is at high risk for 
bleeding complications.  
 
Record the required information on the appropriate CRF.  
• Transthoracic  Echocardiogram (TTE)  or angiogram – Intra-procedural  
o PDA measure ments  to confirm eligibility  
 Study Document No: SJM-CIP-[ZIP_CODE]   Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page 17 of 51 
• Procedural data (including access site, medications (heparin dose), hemodynamics (gradients 
derived from echocardiography), contrast usage (use of contrast is opt ional) & fluoroscopy, device 
deployment)  
• Evaluation and data collection of any reportable adverse events  
 
Subjects that are enrolled (i.e. have a TorqVue™ LP Catheter inserted ), but do not have an ADO II AS 
study device implanted will be followed thr ough the 30 day follow -up visit.  Adverse events will be collected 
either in -person or via telephone as documented in section 8.2 . Sponsor Representatives may be involved 
in providing support during the implant/procedure.  
5.3.[ADDRESS_358261] -Procedure  
Perform the followi ng assessments  within 48 hours  after the procedu re and prior to discharge : 
• Physical exam (PE)  – including murmur evaluation  
• Chest X -ray (CXR) – Anteroposterior view 
• Electrocardiogram (ECG)  
• Transthoracic echo (TTE)  
• Evaluation and data collection of any reportable adverse events  
 
At the post -procedure visit , the following additional procedures may be required (refer to Table 6 for 
criteria):  
• Lung Perfusion sc an 
• Aortic Catheterization  (or other confirmatory testing  such as cardiac CT/MRI ) 
 
Table 4: Post -Procedure Visit Window  
Visit  Window  
Post-procedure  Within 48 hours after procedure and prior to discharge  
 
Subjects should  be on appropriate endocarditis prophylaxis according to the American Heart Association 
recommendations for prophylaxis ( Appendix E).  
 
5.3.5  Scheduled Follow -ups for Pi[INVESTIGATOR_294206] -up visits are scheduled at 1 month , 6 months, 12 months, 24 months,  and 36 months  after the 
device implant/procedure.  The scheduled visit windows are calculated from the enrollment  date (procedure 
date) . 
 
Table 5: Follow -up Windows  
Visit  Window  
1 month  30 days +/- 7 days  
6 months  180 days +/ - 20 days  
12 month  +/- 30 days  
24 month  +/- 60 days  
36 month  +/- 60 days  
 Study Document No: SJM-CIP-[ZIP_CODE]   Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page [ADDRESS_358262] be completed:  
• Physical exam (PE)  – including weight, murmur , femoral pulse, and upper/lower extremity blood 
pressure  evaluation  
• Transthoracic echo (TTE)  
• Evaluation and data collection of any reportable adverse events  
 
At each follow -up visit, the following additional procedures may be required (refer to Table 6 for criteria ): 
• Electrocardiogram (ECG)  
• Lung Perfusion scan  
• Aortic Catheterization (or other confirmatory testing  such as cardiac CT/MRI ) 
 
Sponsor Representatives may be involved in providing support during the Follow -up procedures.  
5.3.[ADDRESS_358263] be 
completed:  
 
• Physical exam (PE)  – including weight, murmur , and femoral pulse  
• Evaluation and data collection of any reportable adverse events  
• TTE (TTE is not required at the 1 month visit for subjects weighing > 2kg at time of enrollment)  
 
The following additional procedures may be required (refer to Table 7 for criteria):  
• Lung Perfusion scan  
• Aortic Catheterization (or other confirmatory testing  such as cardiac CT/MRI ) 
 
If the ductus arteriosus is not effectively closed (Grade 0 or Grade1 shunt) at [ADDRESS_358264] a 12 month follow -up and annually thereafter through the 3 6 month  follow -up via 
telephone. Assessments completed at these follow -ups include:  
• Adverse Event Assessment  – sites should follow patients per their standard of care for any 
reported adverse events.  
 
5.4 Study Flow Chart  
The Study Flow Chart  (Figure 1) and Table 6, Pi[INVESTIGATOR_294207] 7, CAP subjects,  below 
summarize subject flow and requirements of this clinical investigation.  
 
  
 Study Document No: SJM-CIP-[ZIP_CODE]   Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page 19 of 51 
Figure 2: Study Flow Chart  
 
U.S. Non-Randomized 
Trial
Subject Assessed for 
Inclusion / Exclusion CriteriaInformed Consent 
Process
Implant procedure
Subject in Follow-UpNO
 TorqVue™ LP 
Catheter enters body?NOScreen Failure – 
Complete 
Screening LogScreen Failure?
YESScreen Failure – 
Complete 
Screening LogYES
ADO II AS device 
successfully placed?NOSubject followed 
for 30 daysYES
 
 
  
 Study Document No: SJM-CIP-[ZIP_CODE]   Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page 20 of 51 
Table 6:  Schedule of Assessments  for Pi[INVESTIGATOR_294208]-Procedure  5 
1 month  
(30 days  +/- 7 
days)  
6 Month  
(180 days  +/- 20 
days)  
12 Month  
(+/- 30 days)  
24 Month  
(+/- 60 days)  
36 Month  
(+/- 60 days)  
Office Visit  X  X X X X X X 
Informed Consent Process  X        
Demographics  X        
Pregnancy Test1 X        
Medical History  X        
Physical Examination  
(murmur evaluation)  X  X X X X X X 
Chest X -Ray (AP)  X  X      
Electrocardiogram (ECG)  X  X X     
Echocardiogram  (TTE)   X X6 X4 X4 X4 X X X 
Angiogram   X6       
Lung Perfusion Scan 2   (X) (X) (X) (X) (X) (X) 
Aortic catheterization; or other confirmatory testing 3   (X) (X) (X) (X) (X) (X) 
Adverse Event  (X) (X) (X) (X) (X) (X) (X) 
(X) if applicable  
[ADDRESS_358265] be completed prior to the implant procedure . 
 
2 Perform a lung perfusion scan if peak instantaneous gradient in left pulmonary artery is ≥ 35mmHg by 
[CONTACT_6751].  
 
3 Perform aortic catheterization to obtain invasive measurement of the gradient if the mean gradient by 
[CONTACT_294246] ≥ 20mmHg. If aortic catheterization is contraindicated, then an 
alternative imaging study, such as computed tomogr aphy (CT) aortic angiography imaging or magnetic 
resonance (MR) aortic angiography imaging may be utilized. Rationale for not performing aortic 
catheterization shall be specified on the case report form. CT aortic angiography or MR aortic angiography 
may b e used to confirm a significant aortic obstruction whenever there is ≥ 50% diameter narrowing at the 
aortic isthmus.  
 
NOTE  - Alternatively, a clinical exam may be used to confirm aortic obstruction . Rationale for not 
performing a confirmatory imaging study  (aortic catheterization, MR imaging, or CT imaging) shall 
be specified on the case report form.  
 
Exam c riteria = 1) D iminished lower extremity pulses or a blood pressure discrepancy of ≥ 20mmHg 
between the upper and lower extremities  AND 2)  an abnormal ab dominal aortic Doppler pattern 
(blunted profile with diminished upstroke, holo -diastolic antegrade flow , or flow reversal during 
diastole ). 
 
4 If the Echo Core Lab identifies a new significant gradient in the pulmonary artery or the aorta as defined in 
(2) or (3) during the review of the follow -up echocardiograms  through six month s, a lung perfusion scan or 
 Study Document No: SJM-CIP-[ZIP_CODE]   Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page 21 of 51 
aortic catheterization  will be required to determine if the result meets the secondary endpoint . If obstruction 
is detected and confirmed via a lung perfusion scan or aortic catheterization (or other confirmatory testing) 
only an echocardiogram will be required at subsequent follow -up visits.  
 
[ADDRESS_358266] be within 48 hours  after the procedur e and prior to discharge . 
 
6 Either an intra -procedure echocardiogram (TTE) or angiogram will be allowed to confirm the sizing 
inclusion criteria of the PDA length (≥ 3 mm) and PDA diameter (≤ 4 mm) prior to inserting the TorqVue™ 
LP Catheter into vasculature.  
 
Table 7: Schedule of Assessments for CAP  Subjects  
    Visit 
 
 
 
 
 
Study Activity  
Baseline  
Procedure  
Post-Procedure  5 
1 month  
(30 days +/- 7 
days)  
6 Month  
(180 days  +/- 20 
days)  
12 Month  
(+/- 30 days)  
24 Month  
(+/- 60 days)  
36 Month  
(+/- 60 days)  
Office Visit  X  X X X    
Telephone Visit       X8 X X 
Informed Consent Process  X        
Demographics  X        
Pregnancy Test1 X        
Medical History  X        
Physical Examination  
(murmur evaluation)  X  X X X    
Chest X -Ray (AP)  X  X      
Electrocardiogram (ECG)  X  X      
Echocardiogram  (TTE)   X X6 X4 X4, 7 X4 (X)8   
Angiogram   X6       
Lung Perfusion Scan 2   (X) (X) (X)    
Aortic catheterization; or other confirmatory testing 3   (X) (X) (X)    
Adverse Event  (X) (X) (X) (X) (X) (X) (X) 
(X) if applicable  
[ADDRESS_358267] be completed prior to the implant procedure . 
 
2 Perform a lung perfusion scan if peak instantaneous gradient in left pulmonary artery is ≥ 35mmHg by 
[CONTACT_6751].  
 
3 Perform aortic catheterization to obtain invasive measurement of the gradient if the mean gradient by 
[CONTACT_294246] ≥ 20mmHg. If aortic catheterization is contraindicated, then an 
alternative imaging study, such as computed tom ography (CT) aortic angiography imaging or magnetic 
resonance (MR) aortic angiography imaging may be utilized. Rationale for not performing aortic 
catheterization shall be specified on the case report form. CT aortic angiography or MR aortic angiography 
may be used to confirm a significant aortic obstruction whenever there is ≥ 50% diameter narrowing at the 
aortic isthmus.  
 
 Study Document No: SJM-CIP-[ZIP_CODE]   Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page 22 of 51 
NOTE - Alternatively, a clinical exam may be used to confirm aortic obstruction . Rationale for not 
performing a confirmatory imaging study (aortic catheterization, MR imaging, or CT imaging) shall 
be specified on the case report form.  
 
Exam criteria = 1) D iminished lower extremity pulses or a blood pressure discrepancy of ≥ 20mmHg 
between the upper and lower extremi ties AND 2)  an abnormal abdominal aortic Doppler pattern 
(blunted profile with diminished upstroke, holo -diastolic antegrade flow , or flow reversal during 
diastole ). 
 
4 If the Echo Core Lab identifies a new significant gradient in the pulmonary artery or the aorta as defined in 
(2) or ( 3) during the review of the follow -up echocardiograms  through six month s, a lung perfusion scan or 
aortic catheterization  will be required to determine if the result meets the secondary endpoint . If obstruction 
is detected and confirmed via a lung perfusion scan or aortic catheterization (or other confirmatory testing) 
only an echocardiogram will be required at subsequent follow -up visits.  
 
[ADDRESS_358268] be within 48 hours after the procedur e and prior  to discharge . 
 
6 Either an intra -procedure echocardiogram (TTE) or angiogram will be allowed to confirm the sizing 
inclusion criteria of the PDA length (≥ 3 mm) and PDA diameter (≤ 4 mm) prior to inserting the TorqVue™ 
LP Catheter into vasculature.  
 
[ADDRESS_358269] weighed > 2kg at the time of enrollment, the 1 month TTE is not required.  
 
8 If the Echo Core lab determines that the ductus arteriosus is not effectively closed (Grade 0 or Grade1 
shunt)  at the [ADDRESS_358270] misses one or more of the scheduled follow -up visits (i.e., does not have a scheduled follow -up 
within the assigned visit windows) without being lost to follow -up, the subject will be consi dered as  having 
 Study Document No: SJM-CIP-[ZIP_CODE]   Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page 23 of 51 
missed the visit (which will be deemed to be a deviation from the CIP and the applicable form should be 
completed). If the subject has missed a visit, the subject shall return for subsequent follow -up visits.  
 
A subject will be considered ‘ Lost to Follow -up’ after two missed visits, a minimum of two  unsuccessful  
phone calls  from investigational site personnel to the subject or contact  [CONTACT_294247] -up visit . 
These two phone calls  must be documented in the subject’s hospi[INVESTIGATOR_1097].  If the subject is deemed lost 
to follow -up, a letter should be sent to the subject’s last known address or  to the subject’s  general 
practitioner (GP). A  copy of the  letter must be maintained in the subject’s hospi[INVESTIGATOR_1097].  
 
When subjec t withdrawal from the clinical investigation  is due to an adverse event the subject will be 
followed  outside of the clinical investigation  until resolution of that adverse event or determination that the 
subject’s condition is stable. The status of the sub ject’s condition should be documen ted at the time of 
withdrawal.  
 
In case of subject withdrawal, the site should make attempts to schedule the subject for a final study visit. At 
this final study visit, the subject will undergo the following assessment s: 
• Physical exam (PE)  
• Evaluation and data collection of any reportable adverse events  
5.8 Requirements for Clinical Laboratories  
An independent Core Lab will be used to r eview and adjudicate the  transthoracic echocardiography (TTE) . 
Service details will be outlined in t he applicable Service Agreement . 
5.[ADDRESS_358271]. Jude Medical, and a statistician. The Publication Committee will be responsible for identifying, selecting 
and approving publication proposals and determini ng authorship according to a Publication Plan.  A 
Publication Committee charter will define membership of the committee and outline the roles and 
responsibilities of the committee, as well as rules to define authorship.  
5.9.2  Clinical Events Committee (CEC)  
An independent CEC will be  responsible for providing review and adjudication of pre-defined clinical events, 
including major and minor complications, deaths , or other events  or endpoints as outlined in the CEC 
Charter . The CEC is responsible for reviewing all report able Adverse Events  as defined in section 8.[ADDRESS_358272] safety 
(e.g. safety -related protocol changes or input regarding study -related adverse event rates).  
 
The primary function, responsibilities and membership of the CEC will be described in detail in a CEC 
charter.  
 
 Study Document No: SJM-CIP-[ZIP_CODE]   Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page 24 of 51 
6 Statistical Considerations  
The following section describes the statistical methods for the clinical investigation  and justification of the 
design. For the Primary and Secondary Endpoints, pi[INVESTIGATOR_294209].   
6.1 Endpoint s  
6.1.1  Primary Safety Endpoint  (IDE and CAP)  
The primary s afety endpoint  is the  rate of  major complications  through  180 days after an attempted ADO II 
AS device implant  (refer to Appendix B for definition) .  
[IP_ADDRESS]  Analysis Methodology  
The proportion of  subjects experiencing a  primary safety endpoint  through 180 days will be estimat ed. The 
95% confidence interval  for the proportion of subjects experiencing a primary safety endpoint will be 
calculated using the exact binomial method . The numerator for the event rate is the numbe r of subjects who 
experienced an event through 180 days . The denominator is the number of subjects in the analysis 
population (see Section [IP_ADDRESS] ). The primary safety endpoint rate will be descriptively compared with the 
rate reported in the literature for the ADO II AS device. The overall estimated rate for major complications 
based o n published literature for the ADO II AS device [1 7-21] is approximately 10.0%.  
[IP_ADDRESS]  Analysis Population  
The primary analysis of the safety endpoint will include enrolled subjects  as defined in section 5.2 excluding 
the following subjects:  
• Subjects with a successful implant who withdraw (e.g., due to death, subject preference or loss -to-
follow -up) before 180 days without an event  
• Subjects who have an unsu ccessful implant who withdraw before 30 days without an event  
6.1.2  Primary Effectiveness Endpoint  (IDE and CAP)  
The primary effectiveness endpoint is the rate of effective  closure of the ductus arteriosus among subjects 
with a successful ADO II AS implant as assessed by [CONTACT_294239] a Grade 0 or Grade 1 shunt 
(see Section 4.4.1 ) at the six -month follow -up by [CONTACT_294240] . 
[IP_ADDRESS]  Analysis Methodology  
The proportions of subjects who have effective  closure of the ductus arteriosus  at the 6 -month follow -up will 
be estimated. The 95% confidence interval  for the rate of effective  closure  of the ductus arteriosus will be 
calculated using the exact binomial method. The numerator for the event  rate is the number of subjects who 
have effective closure of  the ductus arteriosus at 6 -month follow -up. The denominator is the number of 
subjects in the analysis population (see Section [IP_ADDRESS] ). The primary effective ness  endpoint will be 
descriptiv ely compared with the rate reported in the published literature [1 9,20,22] for the ADO II AS device. 
Among subjects successfully implanted with the device the PDA occlusion rate is estimated to be 
approximately 99%.  
[IP_ADDRESS]  Analysis Population  
The primary analysis  of the effectiveness endpoint will include enrolled subjects who achieve a successful 
implant, defined as leaving the catheterization lab with an ADO II AS implanted in the PDA. If a subject has 
more than one  device attempted during the same procedure, but leaves the procedure with an ADO II AS 
device within the ductus arteriosus the procedure is considered successful. Subjects without an implanted 
 Study Document No: SJM-CIP-[ZIP_CODE]   Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page 25 of 51 
ADO II AS device in the ductus arteriosus will be excluded.  Additionally, subjects withdrawn bef ore 6 -month 
follow -up, or with no data for residual flow by [CONTACT_294248] 6 -month follow -up visit will be excluded.  
6.1.3  Secondary Endpoint (IDE and CAP)  
The secondary endpoint is the rate of significant ob struction of the pulmonary artery or aorta through the 6 -
month follow -up visit  per the following definitions:  
1. Significant obstruction of the left pulmonary artery is defined as less than 30% flow to the left lung 
by [CONTACT_294242] a peak instantane ous gradient in left pulmonary artery ≥35 mmHg by 
[CONTACT_294243].  OR 
2. Significant obstruction of the aorta is defined as a gradient of ≥20 mmHg in the aortic isthmus by 
[CONTACT_294244] a mean gradient ≥20 mmHg in the aortic isthmus by 
[CONTACT_294245].  
[IP_ADDRESS]  Analysis Methodology  
The proportions of  subjects experiencing a secondary  endpoint  through the 6 -month follow -up visit  will be 
estimat ed. The 95% confidence interval  for the proportion of subjects experiencing a secondary  endpoint 
will be calculated using the exact binomial method . The numerator for the event rate is the number of 
subjects who experience an event by [CONTACT_941] 6 -month follow -up visit . The denominator is the number of 
subjects in the analysis population (see Section [IP_ADDRESS] ).  
[IP_ADDRESS]  Analysis Population  
The analys is of the secondary endpoint will include all enrolled subjects who achieve a successful implant, 
which is defined as leaving the catheterization lab with an ADO II AS implanted in the PDA. If a subject has 
multiple devices attempted during the same procedure, but leaves procedure with an ADO II AS device 
within the ductus arteriosus the procedure is considered successful . Subjects without an implanted ADO II 
AS device in the ductus arteriosus will be excluded.   Additionally, subjects withdrawn before [ADDRESS_358273] the 6 -month follow -up endpoint data and do 
not experience an event ( aortic or pulmonary obstruction)  before 6 -month follow -up will also be excluded.  
6.1.4  Descriptive Endpoint s and Additional Data  for Pi[INVESTIGATOR_294210].  
• Implant  success: 
The frequency and percentage of implant success  (defined in Section [IP_ADDRESS] ) will be reported . This 
analysis will include enrolled subjects.  
• PDA shunt status at each follow -up visit : 
The frequency and percentage of PDA shunt status at each follow -up visit, as assess ed by [CONTACT_294249],  will be reported . Shunt size s categories  are: Grade 0/1, 2, and Grade 3/4. This analysis will 
include subjects who achieve a successful implant.  
• Obstruction measurements at each follow -up visit : 
The frequency and percentage of sign ificant obstruction of the left pulm onary artery and the frequency 
and percentage of significant aortic obstruction (defined in Section 6.1.3 ) at each follow -up visit will be 
reported. Both analys es will include subjects who achieve a successful implant.   
• Major and Minor Complications : 
The frequency and percentage of major and minor complications (ref er to Appendix B for definition ) 
from the time of the implant procedure will be reported.  
• Death : 
The frequency and percentage of death will be repor ted. 
 Study Document No: SJM-CIP-[ZIP_CODE]   Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page 26 of 51 
• Additional data :  
Demographics and baseline characteristics, procedure information , left ventricular function and 
dimensions, pulmonic and tricuspid regurgitation, adverse events, withdrawal and protocol deviations  
will also be summarized.    
6.1.5  Descriptive Endpoints and Additional Data  for CAP  Subjects  
The following endpoints will be summarized using descriptive statistics.  
• Implant  success : 
The frequency and percentage of implant success  (defined in Section [IP_ADDRESS] ) will be reported . This 
analysis will include enrolled subjects.  
• Major and Minor Complications : 
The frequency and percentage of major and minor complications (ref er to Appendix B for definit ion) 
from the time of the implant procedure will be reported.  
• Death : 
The frequency and percentage of death will be reported . 
• Additional data:  
Demographics and baseline characteristics, procedure information, left ventricular function and dimensions 
and p ulmonic and tricuspid regurgitation at 6 months, and adverse events, withdrawal and protocol 
deviations  will also be summarized at each follow -up visit.   
6.2 Justification of Clinical Investigation Design  
Based on the clinical observations and safety profile established through over 5400 ADO II AS devices 
shipped internationally , published literature with the ADO II AS device outside the [LOCATION_002], and 
previous internally run clinical studies examining ADO II AS, a single arm, prospective, multicen ter, non -
randomized clinical investigation is designed to characterize  the safety and effectiveness of the ADO II AS 
device in small infants with a patent ductus arteriosus (PDA). Additionally, the device characteristics are 
very similar to the FDA -approve d ADO II and AMPLATZER Vascular Plug II (AVP II) devices.  
6.3 Overall Sample Size  for Pi[INVESTIGATOR_294211] a modified version of a previously FDA approved device (ADO II) for the same lesion, but 
in smaller sizes  and lower profile retention di scs. The ADO II AS represents a line -extension to ADO II. 
Furthermore, the ADO II AS device has been commercially available in Europe since [ADDRESS_358274] been published and provide confidence that the device is safe and effective. Therefore, a 
minimum sample size of 40 subjects (minimum of 15 subjects ≤2 kg) at up to [ADDRESS_358275] enrollment in the ADO II AS study, wi th additional prospective collection of safety and 
effectiveness data on the ADO II AS device upon enrollment completion in the pi[INVESTIGATOR_294212].   
 
 Study Document No: SJM-CIP-[ZIP_CODE]   Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page 27 of 51 
6.5 Timing of Ana lysis  for Pi[INVESTIGATOR_170822]  
A pre -market approval (PMA) application will be submitted after [ADDRESS_358276] implant attempt. A minimum of 15 subjects will be enrolled with a weight ≤ 2 kg. In the event 
there is difficulty in enrolling 15 subjects w ith a weight of < 2 kg, a PMA application will be submitted after 
25 subjects with weight > [ADDRESS_358277] reached 6 months of follow -up. An additional submission will be done 
when 15 subjects with a weight of < [ADDRESS_358278] -approval requirements.  
6.6 Success Criteria  for Pi[INVESTIGATOR_294213]. The safety and 
effectiveness results will be compared with data reported in the literature.   
6.7 Deviations from Statistical Plan  
If any deviations from the original statistical plan occur, such devi ations will be documented in the clinical 
study report or statistical report containing the analysis results.  
7 Risks and Benefits  
Risks associated with the device are managed in accordance with ISO [ZIP_CODE]. The risk analysis included an 
objective review of published and available unpublished medical and scientific data. The sections below 
provide an  overview of residual risks identified in the risk management report and anticipated benefi ts of the 
medical device. The  additional tests and assessments required by [CONTACT_294250] l investigation, and are incorporated in the sections  below . 
7.1 Risks associa ted with the Device under  Investigation  
7.1.1  Anticipated Adverse Device Effects  
The risks associated with the implant procedure are similar to those of other cardiac catheterization 
proce dures in infants and children  and are documented below . Radiation risks associated with the 
procedure are comparable to a diagnostic catheterization procedure.  
 
• Air embolism  
• Allergic reaction  
• Arrhythmia  
• Arteriovenous fistulae  
• Bleeding at the access site  
• Brachial plexus injury  
• Bruising  
• Cardiac tamponade  
• Death  
• Deep venous thrombosis  
• Dissection  
• Embolism  
• Endocarditis  
• Hematoma  • Hemodynamic compromise  
• Infection  
• Myocardial infarction  
• Perforation  
• Peripheral pulse loss  
• Pseudoaneurysm  
• Respi[INVESTIGATOR_1506]  
• Stroke/transient ischemic attack  
• Thrombosis  
• Valve damage  
• Vascular access site injury  
• Vascular occlusion  
• Vessel damage  
 Study Document No: SJM-CIP-[ZIP_CODE]  Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page [ADDRESS_358279] of the anticipat ed adverse device effects associated with the ADO II AS device  under 
investigation : 
 
• Air embolism  
• Allergic dye reaction  
• Allergic drug reaction  
• Anesthesia reactions  
• Apnea  
• Arrhythmia  
• Bacterial endocarditis  
• Bleeding  
• Cardiac perforation  
• Cardiac tamponade  
• Chest pain  
• Device embolization  
• Device erosion  
• Death  
• Fever  
• Hemolysis  
• Headache/migraine  
• Hypertension  
• Hypotension  
• Myocardial infarction  
• Nickel sensitization  
• Nickel toxicity  
• Palpi[INVESTIGATOR_814]  
• Partial obstruction of the Aorta  
• Partial obstruction of the Pulmonary Ar tery 
• Pericardial effusion  
• Pericarditis  
• Peripheral embolism  
• Pleural effusion  
• Pulmonary embolism  
• Reintervention for device removal  
• Stroke  
• Transient ischemic attack  
• Thrombus  
• Valvular regurgitation  
• Vascular access site injury  
• Vessel perforation  
• Carcinogenicity  
 
Potential carcinogenicity risk . The ADO II AS device consists of a nickel -titanium alloy.  In vitro testing has 
demonstrated that that nickel is released from this device for a minimum of [ADDRESS_358280] also been associated with carcinogenicity (ability to cause cancer) in animal models. In humans, 
carcinogenicity has been demonstrated only through an inhalation route (breathing nickel in), which will  not 
occur with this procedure.  
 Study Document No: SJM-CIP-[ZIP_CODE]  Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page 29 of 51 
7.1.1  Risks associated with Clinical In vestigation Assessments  
The risks associated with the ADO II AS device implant procedure are similar to those of other cardiac 
catheterization procedures.  Radiation risks associated with the procedure are comparable to a diagnostic 
catheterization procedur e. 
 
The risks associated with the ADO II AS device are similar to other implantable c ardiac occlusion devices.   
 
Additional study required procedures are listed below with the associated risks/discomforts.  
 
Blood Draw  
There may be some minor discomfort and/or anxiety associated with drawing blood including pain or bruising 
associated with the needle from the blood draw.  Fainting and local infection can also occur . 
 
Aortic Catheterization  
Aortic catheterizations have a risk for injury to the vessel, allergic  reaction to dye, anesthesia reaction 
irregular heartbeat, infection, poisonous products in the bloodstream, loss of blood flow to the extremities 
from the catheter placement, damage or injury to the heart, lungs, valves or vessels from the catheter or wir e 
advancement, air or blood clot formation in a vessel or heart which may cause temporary or complete 
blockage of blood flow to the heart, brain, or extremities, irregular blood pressure, fever, injury to the nerves 
that control the arm or shoulder, kidney  dysfunction due to exposure to contrast media (liquid used for 
imaging) and death.  
 
Lung Perfusion Scan  
Lung perfusion scans expose the patient to a small dose of radiation ( about as much radiation as natural 
exposure  over a year ). There is always a slight risk from being exposed to radiation.  
 
Computed Tomography (CT) Aortic Angiography  
There may be risks due to the radiation used during the CT imaging. There is also a risk for an allergic 
response to the contrast media/dye used  during the CT imaging procedure.  
 
Magnetic Resonance (MR) Aortic Angiography  
MR imaging use magnetic and radio waves to generate images of the vasculature. The risk from these waves 
is no greater than experienced in daily life. There is also a risk for an allergic response to the contrast 
media/dye used during the MRI procedure.  
 
Echocardiogram  
The electrodes placed on subject’s  chest may cause discomfort such as redness or itching. The subject may 
feel slight pressure from the transducer or probe that the technician utilizes to take measurements .  
 
Chest X -ray 
The risks of c hest x -rays include exposure to small doses of radiation  (about as much radiation as natural 
exposure over 10 days ). There is always a slight risk from being exposed to any radiation . 
 
Electrocardiogram  
The electrodes  placed on subject’s  chest can sometimes cause discomfort such as redness or itching.  
 Study Document No: SJM-CIP-[ZIP_CODE]  Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page 30 of 51 
7.2 Possible interactions  with concomitant treatments  
The risks from intra -procedural medications administration upon undergoing ADO II AS implant are no 
different from the risks associated with medications prescribed during a cardiac catheterization procedure or 
implant of  commercially available tra nscathete r PDA occluder device.  
7.3 Risk Con trol Measures  
Every possible effort will be taken to minimize the risks, in cluding:  
• Careful selection of experienced Investigators for the clinical investigation  
o Cardiologists with training and education in pediatric cardiol ogy and experience using 
transcatheter techniques to close PDAs  
o Prior experience with transcatheter closure procedure s using  devices such as ADO, ADO II 
or other similar devices  with a minimum of [ADDRESS_358281] the necessary infrastructure to support trial procedures:  
▪ Cardiac catheterization lab or NICU bedside capability  to perform  intra-procedural 
echocardiography and fluoroscopy  
▪ Anesth esiology support, as needed  
▪ Cath eterization laboratory, operating room , post anesthesia recovery, intensive care 
and step down unit spaces to accommodate cases with and without complications  
▪ On-site emergency cardiac surgery services  
• Adequate monitoring for each clinical investigation site  
• Conducting the clinical investigation in accordance with the CIP, all applicable laws and regulations 
and any conditions of approval imposed by [CONTACT_294251]  
• Preparati on of the ADO II AS device and implant procedure in accordance with the device IFUs  
• Training of Investigators both on the CIP and ADO II AS implant procedure  
o All site staff will participate and complete a training module on the CIP  
o All implanting physician s must comple te an implanter training module  
o Implanting physicians  with no prior successful transcatheter PDA closure experience with 
ADO II AS in small infants (≤2 kg)  will receive  proctoring for a minimum on one case . 
• Assessment of continuing safety of s ubjects in the clinical investigation by [CONTACT_294252] s have also been taken to reduce the risks of specific study device related adverse 
events:  
• Subject eligibility criteria include maximum  diameter and minimum lengths of the PDA to be treated 
with the ADO II AS which should reduce the likelihood of partial obstruction of the pulmonary artery 
or aorta.  
• Whenever possible, subjects will be given a loading dose of Heparin at the beginning of the  
procedure to reduce the risk of thrombus formation on the devices.  The use of heparin in patients 
with a risk of bleeding is considered optional.  
• The physicians will be trained on the procedure, specifically device size selection and placement, to 
reduce the risk of device embolization, partial obstruction of the aorta or pulmonary artery and 
hemolysis which could be potentially caused by [CONTACT_294253].  
• The physicians will be instructed to use their clinical judgement to monitor subjects for potential 
adve rse events related to nickel and to report such events with the goal of protecting the welfare of 
the subject if the root cause of the adverse event is determined to be nickel related, paying special 
attention to subjects weighing less than 6kg at baseline  
 Study Document No: SJM-CIP-[ZIP_CODE]  Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page 31 of 51 
• The physicians will be encouraged to utilize an ante rograde implant approach, while avoiding the 
need for arterial access. Additionally, the protocol will not require the acquisition of invasive 
hemodynamic measurements to minimize complication and shorte n procedure time. Device implant 
is recommended to be performed based on echocardiographic and fluoroscopic guidance without 
needing to utilize intravenous contrast agents and angiograms.  
• Physicians are required to follow The American Heart Association Rec ommendations for 
endocarditis prophylaxis during the clinical study.  
7.[ADDRESS_358282] been no rec alls or field actions during the global marketing and sale of the ADO II AS device.  
8 Requirements for Investigator records and reports  
8.1 Deviations from CIP  
A deviation is defined as an instance(s) of failure to follow, intentionally or unintentionally, the requirements of 
the CIP. The investigator should not deviate from the CIP.  
 
In some cases, failure to comply with the CIP may be considered failure to protect the rights, safety and well -
being of subjects; such non -compliance exposes s ubjects to unreasonable risks. Examples: failure to adhere 
to the inclusion/exclusion criteria, failure to perform safety assessments intended to detect adverse events. 
Investigators should seek to minimize such risks by [CONTACT_110596].  
 
The PI [INVESTIGATOR_294214] m aintain accurate, complete, and current records, including documents showing the date of and 
reason for each deviation from the CIP. Relevant information for each deviation will be documented as soon 
as possible on the applicable CRF. The site will submit the CRF to the Sponsor.  
 
The PI [INVESTIGATOR_110568] . 
 
An investigator shall notify the Sponsor and the reviewing IRB of any deviation from the investigational plan 
to protect the life or ph ysical well -being of a subject in an emergency. Such notice shall be given as soon as 
possible, but in no event later than 5 working days after the emergency occurred. Except in such an 
 Study Document No: SJM-CIP-[ZIP_CODE]  Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page [ADDRESS_358283] the scientific soundness of the plan or the rights, safety, or welfare of 
human subjects, FDA and IRB is also required.  
8.2 Adverse Event R eporting  
Safety surveillance within this trial (an d the safety reporting performed by [CONTACT_093]), starts as soon as 
the subject is enrolled . The safety surveillance and the safety reporting will continue until the last 
investigational visit has been performed, the subject is deceased, the subject/i nvestigator concludes his /her 
participation into the clinical investigation or the subject withdrawal from the clinical investigation.  
 
All adverse event data  required to be reported  will be collected throughout the clinical investigation and will 
be repor ted to the Sponsor on a CRF.  
 
Adverse events will be monitored until they are adequately resolved  or the subject has ended his/her 
participation in the trial, whichever comes first. The status of the subject’s condition should be documented at 
each visit.  
 
For the purposes of this clinical investigation the following events will be reported (see Appen dix B for 
definitions):  
• Unanticipated adverse device effects  
• All adverse events viewed/interpreted  by [CONTACT_294254] a) the implant 
procedure or b) the study device  (ADO II AS)  regardless of seriousness  
 
Note – If relatedness is unknown  or cannot be determined, then the event must be reported . 
 
Note – if a procedure is abandoned and a non -study device is used to close the PDA, adverse events  
associated with the non -study device will not be reported.  
 
Records relating to the subject’s subsequent medical course must be maintained and submitted (as 
applicable) to the Sponsor until the event has subsided or, in case of permanent impairment, until the event 
stabilizes and the overall clinical outcome has been ascertained. Adverse events will be monitored until they 
are adequately resolved.  The status o f the subject’s condition should  be documented at each visit.   
 
SAE Reporting  
Reportable adverse events that are deemed by [CONTACT_294255].  
 
Clinical Sit e Reporting timelines  
All Sites  SAEs must be reported to the Sponsor no later than 3 calendar days from the day 
the site personnel became aware of the event or as per the investigative site’s local 
requirements, if the requirement is more stringent than t hose outlined  above . 
 
The date the site staff became aware the event met the criteria of an SAE must be recorded in the source 
document.  The Investigator will further report the SAE to the local IRB/EC according to the institution’s 
IRB/EC reporting requirements.  
 
 Study Document No: SJM-CIP-[ZIP_CODE]  Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page [ADDRESS_358284] deaths will be documented and reported to the Sponsor as soon as possible (but no later than 3 
calendar  days) after becoming aware of the event via the applicable CRF.  
8.2.[ADDRESS_358285] notify the Sponsor and the IRB 
immediately, but no later than 3 calendar  days of the investigator’s knowledge of the event, as required by 
21 CFR §812.150. St. Jude Medical will take any s teps necessary to investigate the event, and, as 
appropriate, will be responsible for notifying FDA and all other participating IRBs and investigators.  
8.2.[ADDRESS_358286]. Jude Medical (SJM) Postmarket Surveillance Department 
by [CONTACT_294256]  [EMAIL_5779]  or cal ling [ADDRESS_358287] complete an AE Case Report Form (CRF) including the 
information on the complaint and report to St Jude Medical as soon as p ossible.  
 
Should a subject death be caused by [CONTACT_294257], the investigator 
should  complete a Form 3500A (MedWatch) and submit to SJM and the FDA  within 10 days after becoming 
aware of the event . 
8.3 Source  records  
Source documents will be created and maintained by [CONTACT_294258] . The data reported on the CRFs will be derived from, and be consistent with, these source 
documents, and any discrepancies will be explaine d in writing.  
8.4 Records retention  
The Sponsor and the Principal Investigators will maintain the clinical investigation documents as required. 
Measures will be taken to prevent accidental or premature destruction of these documents. The Principal 
Investigator [INVESTIGATOR_110573]/party and document the 
transfer at the investigational site or the Sponsor’s facility, as appropriate.  
 
These documents must be retained by [CONTACT_110602] a period of 2 years after the conclusion of 
the clinical investigation and made available for monitoring or auditing by [CONTACT_1034]’s representative or 
representatives of the applicable regulatory agencies.  
 
All original source documents must be stored for the maxi mum time required by [CONTACT_110603][INVESTIGATOR_307], research institute, or practice in question. If original source documents can no longer be maintained 
at the site, the investigator will notify the Sponsor.  
9 Clinical Data Handling  
The Sponsor will be r esponsible for the data handling. The Sponsor and/or its affiliates will be responsible for 
compi[INVESTIGATOR_294215]. Data will be analyzed by [CONTACT_294259]: SJM-CIP-[ZIP_CODE]  Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page 34 of 51 
and may be transferred to the Sponsor’s locations world wide and/or any other worldwide regulatory authority 
in support of a market -approval application.  
9.[ADDRESS_358288] and confidentiality of his/her information will be preserved in 
reports and when publishing any data. Confidentiality of data will be observed by [CONTACT_294260]. All data will be secured against unauthorized access.  
9.2 Data Management Plan  
A Data Management Plan (DMP) will describe procedures used for data review, database cleaning, and 
issuing and resolving data queries. If appropriate, the DMP may be updated throughout the clinical 
investigation duration. All revisions will be tracked and document controlled.  
 
Subject data will be captured in a validated electronic data capture (EDC) system hosted by [CONTACT_1034].  
 
Only authorized site personnel will be  permitted to enter the CRF data through the EDC system deployed by 
[CONTACT_99894]. Jude Medical. An electronic audit trail will be used to track any subsequent changes of the entered data.  
9.3 Document and Data Control  
9.3.1  Traceability of Documents and Data  
The investigator will ensure accuracy, completeness legibility and timeliness of the data reported to the 
Sponsor on the CRFs and in all required reports.  
9.3.2  Recording Data  
The CRF will be reviewed by [CONTACT_110608]. An appropriate comment will be provided to 
explain changes to data reported on the CRF.  
10 Monitoring  
It is the responsibility of the Sponsor to ensure the clinical investigation is conducted, recorded and reported 
according to the approved CIP, subsequent amendment(s), applicable regulations and guida nce documents.  
 
Monitoring will be conducted according to St. Jude Medical’s Clinical Monitoring work instruction.  
Prior to beginning the clinical investigation, the Sponsor will contact [CONTACT_294261]. A designated monitor will periodically review the subject 
records and associated source documents. The investigator shall make subject and clinical investigation 
records available to the clinical monitor for monitoring.  
[ADDRESS_358289] current version of the World Medical Association (WMA) Declaration of Helsinki 
 Study Document No: SJM-CIP-[ZIP_CODE]  Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page [ADDRESS_358290] to the clinical investigation, that information will be forwarded to the Sponsor.  
11.2 Quality Assurance audits and Regulatory I nspections  
The investigator and/or delegate should contact [CONTACT_294262] a regulatory  
authority inspection at the site. A monitor or designee will assist the investigator and/or delegate in preparing 
for the audit. The Sponsor may perform quality assurance audits, as required.  
 
The Principal Investigator [INVESTIGATOR_294216], audits, IRB review and regulatory authority inspections, as required. The 
Principal Investigator [INVESTIGATOR_294217] f rom the 
subject, hospi[INVESTIGATOR_294218].  
11.3 Repeated and Serious Non -Compliance  
In the event of repeated non -compliance or a one -time serious non -compliance, as determined by [CONTACT_429], a monitor or designee will attempt to secure compliance by [CONTACT_294263]:  
• Visiting the investigator,  
• Contact[CONTACT_115691],  
• Contact[CONTACT_115692],  
• Retraining of the investigator.  
 
If an in vestigator is found to be repeatedly non -compliant with the signed agreement, the CIP or any other 
conditions of the clinical investigation, the Sponsor will either secure compliance or, at its sole discretion, 
terminate the investigator’s participation in  the clinical investigation. In case of termination, the Sponsor will 
inform the responsible regulatory authority, as required, and ensure that the IRB is notified, either by [CONTACT_1268] [INVESTIGATOR_294219].  
12 Suspension or premature termination  of the clinical investigation  
The Sponsor reserves the right to terminate the clinical investigation at any stage, with appropriate written 
notice to the investigators, IRB and relevant Regulatory authorities, if required.  
 
A Principal Investigator, IRB or regulatory authority may suspend or prematurely terminate participation in a 
clinical investigation at the investigational sites for which they are responsible. The investigators will follow 
the requirements specified in the Clinical Trial Agreement.  
 
If suspi[INVESTIGATOR_294220], the Sponsor may suspend the clinical investigation while the risk is 
assessed. The Sponsor will terminate th e clinical investigation if an unacceptable risk is confirmed. If the 
Sponsor completes an analysis of the reasons for the suspension, implements the necessary corrective 
 Study Document No: SJM-CIP-[ZIP_CODE]  Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page [ADDRESS_358291] of safety, the Sponsor will inform all other Principal Investigators.  
 
If suspension or premature termination occurs, the Sponsor will remain responsible for providing resources to 
fulfill the obligations fro m the CIP and existing agreements for following up the subjects enrolled in the clinical 
investigation, and the Principal Investigator [INVESTIGATOR_294221]/her investigational site, if appropriate.  
13 Clinic al Investigation Conclusion  
The clinical investigation will be concluded when:  
• All sites are closed AND  
• The final report has been provided to investigators or the Sponsor has provided formal 
documentation of clinical investigation closure.  
[ADDRESS_358292]. Jude Medical’s 
publication policy, which is based on Good Publication Practices and International Committee of Medical 
Journal Editors (ICMJE) guidelines. A co py of the policy will be provided upon request of the investigator.  
Publication planning and authorship determinations will be overseen by [CONTACT_201288] (see 
section 5.10.1 ), and investigators will be notified via email about the dissemination  of study data and 
opportunities for involvement as authors on publications/presentations.  
[ADDRESS_358293]. If this clin ical investigation is terminated early, the Sponsor will 
make every effort to hasten the release of the pre -specified outcomes through the ClinicalTrials.gov website.  
  
 Study Document No: SJM-CIP-[ZIP_CODE]  Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page 37 of 51 
Appendix  A: CIP Revisions  
 
Procedure for CIP Amendments  
 
This c linical investigation plan  will be amended as needed throughout the clinical investigation . Rationale  
will be included with each amended version in the Revision History table below . The version number and date 
of amendments will be documented. The amendment will i dentify if it is mandatory or optional to implement 
the amendment.  
 
Special considerations will be made when the changes affect the investigational device design and/or 
patients’ safety, rights and well -being.  
 
Amendments to the CIP will  originate from the Sponsor. The approval of the Coordinating Investigator (if 
applicable) and the Principal Investigators will be collected on the signature [CONTACT_1787] .  
 
As appropriate, IRB and regul atory authorities will be notified of amendments to the CIP a nd subject Informed 
Consent.  
 
Administrative changes to or formal clarifications of  the CIP are allowed. They will be documented in writing 
and provided to the investigators. This information will be incorporated when an amendment occurs.  
 
Revision History  
 
Amendment 
Number  Version  Date  Rationale  Details  
Not 
Applicable  A [ADDRESS_358294] been 
made for clarity of procedures 
and/or analysis methods.  
2. Language in Section 5 
‘Procedure’ section aligns with 
language in 5.4.1 
Implant/Procedure section.  
3. Change was made to bring the 
protocol into alignment with 
the Instructi ons for Use.  
4. Removed  exclusion criteria 
regarding gestational age < 24 1. Replaced SJM logo with 
Abbott logo  and clarified 
details throughout the 
CIP.  
2. Specified subjects that do 
not receive the device at 
time of implant will be 
followed for 30 days and 
withdrawn  in Section 5 
‘Procedures’ . 
3. Allow use of intra -
procedure angiogram to 
confirm the sizing 
inclusion criteria of the 
 Study Document No: SJM-CIP-[ZIP_CODE]  Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page 38 of 51 
Amendment 
Number  Version  Date  Rationale  Details  
weeks as other exclusion 
criteria requiring ‘weight 
greater than 700g at time of 
implant’ and ‘other disease 
process likely to limit survival 
to less than six (6) months’ 
ensure that appropriate 
patients are enrolled. This will 
permit enrollment, for 
example, of a [ADDRESS_358295] -implant.   
5. Added CAP to allow current 
IDE study implanters to 
maintain their technical 
proficiency in ADO II AS 
device implantation and to 
allow additional implanters 
within each of the clinical sites 
activated for the IDE study to 
gain experience with the 
device. Data from the CAP 
may be used to support the 
pre-market approval (PMA) 
application for the AD O II AS 
occluder.  
 PDA length and diameter 
intra-procedure.  
4. Removed  exclusion 
criteri on regarding 
gestational age < 24 
weeks.  
5. Added 150 subjects in a 
continued access 
protocol  (CAP) . 
 
3 D 2 Aug 2018  Added 3-day serious adverse 
event (SAE) reporting 
requirement  to align with 
Sponsor procedures  Updated section 8.[ADDRESS_358296] 3-day SAE 
reporting requirement  
 
  
 Study Document No: SJM-CIP-[ZIP_CODE]  Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page 39 of 51 
Appendix  B: Definitions  
Non-study Specific Definitions  
Adverse Event (AE)  
Any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including 
abnormal laboratory findings) in subjects, users or other persons, whether or not related to the investigational 
medical device under clinical investigatio n. 
 
This definition includes events related to the investigational medical device  (ADO II AS)  as well as events 
related to the procedures involved  in the clinical protocol . 
 
Serious Adverse Event (SAE)  
An adverse event that led to:  
• Death  
• A serious deterior ation in the health of the subject, that either resulted in:  
o A life -threatening illness or injury OR  
o A permanent impairment to a body structure or a body function OR  
o An in -patient or prolonged hospi[INVESTIGATOR_115659]  
o A medical or surgical intervention to preven t life-threatening illness or injury or permanent 
impairment to a body structure or a body function OR 
o A malignant tumor  
• Fetal distress, fetal death or a congenital abnormality or birth defect  
• A planned hospi[INVESTIGATOR_272] a pre -existing condition, or a procedure required by [CONTACT_294264] a serious adverse event.  
 
Adverse Device Effect (ADE)  
An adverse event related to the use of an investigational medical device.  
 
This definition includes adverse events resulting from insuffic ient or inadequate instructions for use, 
deployment, implantation, installation, or operation, or any malfunction of the investigational medical device.  
 
This definition includes any event resulting from the use error or from intentional misuse of the inve stigational 
medical device.  
 
Serious Adverse Device Effect (SADE)  
Adverse device effect that has resulted in any of the consequences characteristic of a serious adverse event.  
 
Unanticipated Adverse Device Effect (UADE)  
As defined in 21 CFR §812.3, unanticipated adverse device effects (UADE) are defined as any serious 
adverse effect on health or safety or any life -threatening problem or death caused by, or associated with, a 
device, if that effect, problem, or death was not previously identified in n ature, severity, or degree of incidence 
in the CIP or application (including a supplementary plan or application), or any other unanticipated serious 
problem associated with a device that relates to the rights, safety, or welfare of subjects.  
  
 Study Document No: SJM-CIP-[ZIP_CODE]  Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page 40 of 51 
Study Speci fic Definitions  
Related:  
The adverse event is related to the study device/procedure – i.e. an event that follows a reasonable temporal 
sequence from administration of the study intervention, follows a known or expected response pattern to the 
suspected int ervention, that is confirmed by [CONTACT_3895][INVESTIGATOR_294222]’s 
clinical state.  
 
In summary, the AE is related to the study  device  (ADO II AS)  or procedure if the event satisfies all of 
following criteria:  
• Has a reasonable temporal relationship to intervention (e.g. device implant)  
• Could not readily have been produced or explained by [CONTACT_423]’s clinical state or have been d ue to 
environmental or other interventions  
• Follows a known pattern of response to intervention  
• Disappears or decreases with reduction in dose or cessation of intervention and recurs with re -
exposure  
 
Attempted ADO II AS Device Implant  
Insertion of the TorqVue™ LP Catheter (9 -TVLPC4F90/080)  into the vasculature of the subject.  
 
Major Complication  
Major complications are defined as device (ADO II AS) or procedure -related adverse events resulting in a ny 
of the following:  
• death,  
• life-threatening adverse event,  
• persistent or significant disability/incapacity, and/or  
• a major open surgical intervention which is performed by a surgeon under general anesthesia  
 
Examples of Major Complications:  
• Device or procedure related events lead ing to d eath 
• Cardiac perforation requiring percutaneous (e.g., pericardiocentesis) or open surgical intervention  
• Cardiac tamponade  
• Embolization requiring open surgical procedure (e.g., open heart surgery or femoral vessel cutdown 
procedure) to retrieve the  device  
• Persistent hemodynamic instability requiring emergency cardioversion/defibrillation therapy or 
emergency blood transfusion and/or institution of inotropic therapy  
• Excessive blood loss or hemolysis requiring transfusion  ≥ 20 cc/kg  
• Persistent or worsening respi[INVESTIGATOR_34300]  
• Cerebral or pulmonary embolism  
• Persistent cardiac arrhythmia requiring a pacemaker  
• Arteriovenous fistula requiring open surgical intervention  
• False aneurysm of the femoral artery requiring surgical interventi on 
• Femoral vessel t hrombophlebitis treated with intravenous antibiotics  
• Infection of the device (bacterial endocarditis)  
 
  
 Study Document No: SJM-CIP-[ZIP_CODE]  Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page 41 of 51 
Minor Complication  
Minor complications are defined as device  (ADO II AS)  or procedure -related adverse events that do not fit the 
definition of a major complication. These will include adverse events which may require medical intervention 
but are not life threatening, are not likely to have long -term (> 6 months) sequelae, and do not require long 
term (> 6 months) therapy. The following  are examples of adverse events considered to be minor 
complications:  
 
Examples of Minor Complications:  
• Embolization that occurs intra -operatively where the device is retrieved using a transcatheter 
approach (e.g., using a snare) without needing to perform an open surgical procedure, such as open 
heart surgery or an open femoral vessel cutdown procedure.  
• Reduced peripheral pulse (reversible) that can be managed with anti -thrombotic therapy (e.g., 
heparin, Aspi[INVESTIGATOR_248])  
• Cardiac perforation not requiring percutaneous (e.g., pericardiocentesis) or open surgical intervention  
• Transient c ardiac arrhythmia  that is manage d successfully with  cardioversion or medication  
• Hematoma of the groin not requiring open surgical intervention  
 
 
  
 Study Document No: SJM-CIP-[ZIP_CODE]  Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page 42 of 51 
Appendix  C: Labels  
 
The approved product labeling will be kept under a separate cover and available upon request for FDA or IRB 
submissions.  
 
  
 Study Document No: SJM-CIP-[ZIP_CODE]  Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page 43 of 51 
Appendix  D: Bibliography  
1. Tashiro, Jun, Eduardo A. Perez, and Juan E. Sola. "Reduced Hospi[INVESTIGATOR_294223], Extremely Low Birth Weight Infants: A Propensity Score -matched 
Outcome S tudy."Annals of surgery  (2015).  
2. Schneider, Douglas J. "The patent ductus arteriosus in term infants, children, and adults." In Seminars in 
perinatology, vol. 36, no. 2, pp. 146 -153. WB Saunders, 2012.  
3. Mahoney LT, Coyell KG, Laurer RM:  The Newborn Transitional Circulation:  Two-dimensional Doppler 
Echocardiographic Study.  J Am Coll Cardiol  1985;6:623.  
4. Philip, Ranjit, B. Rush Waller, Vijaykumar Agrawal, Dena Wright, Alejandro Arevalo, David Zurakowski, 
and Shyam Sathanandam. "Morphologic characterization of the patent ductus arteriosus in the premature 
infant and the choice of transcatheter occlusion dev ice." Catheterization and Cardiovascular Interventions 
(2015).  
5. Krichenko A, Benson LN, Burrows P, et al: Angiographic classification of the isolated, persistently patent 
ductus arteriosus and implications for percutaneous catheter occlusion.  Am J of Card  1989;63:877 -80. 
6. Pass R:  AMPLATZER Duct Occluder Device:  A New Technology for the Closure of the Moderate -to-large -
sized Patent Ductus Arteriosus.  Expert Rev Med Devices 2006;3:291 -296. 
7. Schneider, Douglas J. "The patent ductus arteriosus in term infants, chi ldren, and adults." In Seminars in 
perinatology, vol. 36, no. 2, pp. 146 -153. WB Saunders, 2012.  
8. Moore JW, Levi DS, Moore SD, Schneider DJ, Berdjis F.  Interventional Treatment of Patent Ductus 
Arteriosus in 2004.  Catheter Cardiovasc Interv 2005;64:91 -101. 
9. Perloff, Joseph K. The Clinical Recognition of Congenital Heart Disease . Philadelphi a: Saunders . Print.  
10. Gross RE, Hubbard JP.  Surgical ligation of a patent ductus arteriosus: report of first successful case. 
Congenital Heart Disease,  Hutchinson Ross Pub Co., 1982, p 253.  
11. Kabra, Nandkishor S., et al. "Neurosensory impairment after surgical closure of patent ductus arteriosus 
in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms."  The 
Journal of pediatrics  150.3 (2007): 229 -234. 
12. Chorne, Nancy, et al. "Patent ductus arteriosus and its treatment as risk factors for neonatal and 
neurodevelopmental morbidity."  Pediatrics  119.6 (2007): 1165 -1174.  
13. Teixeira, L. S., et al. "Postoperative cardioresp iratory instability following ligation of the preterm ductus 
arteriosus is related to early need for intervention." Journal of Perinatology 28.12 (2008): 803 -810. 
14. Portsmann W, Wierny L, Warnke H, et al: Catheter closure of patent ductus arteriosus: 62 case s treated 
without thoracotomy. Radiol Clin North Am  1971;9:203 -218. 
15. Weisz, Dany E., and Patrick J. McNamara. "Patent ductus arteriosus ligation and adverse outcomes: 
causality or bias?." Journal of clinical neonatology 3.2 (2014): 67.  
16. Philip, Ranjit, B. Ru sh Waller, Vijaykumar Agrawal, Dena Wright, Alejandro Arevalo, David Zurakowski, 
and Shyam Sathanandam. "Morphologic characterization of the patent ductus arteriosus in the premature 
infant and the choice of transcatheter occlusion device."  Catheterization  and Cardiovascular 
Interventions  (2015).  
17. 17. Gruenstein, Daniel H., et al. "Transcatheter closure of patent ductus arteriosus using the 
AMPLATZER™ duct occluder II (ADO II)." Catheterization and Cardiovascular Interventions 89.6 (2017): 
1118 -1128. Agnolett i, Gabriella, D. Marini, A. M. Villar, R. Bordese, and F. Gabbarini. "Closure of the 
 Study Document No: SJM-CIP-[ZIP_CODE]  Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page [ADDRESS_358297] occluder II additional sizes device."  Catheterization and 
Cardiovascular Interventions  79, no. 7 (2012): 1169 -1174.  
18. Kenny, Damie n, Gareth J. Morgan, James R. Bentham, Neil Wilson, Robin Martin, Andrew Tometzki, Paul 
Oslizlok, and Kevin P. Walsh. "Early clinical experience with a modified Amplatzer ductal occluder for 
transcatheter arterial duct occlusion in infants and small childr en." Catheterization and Cardiovascular 
Interventions  82, no. 4 (2013): 534 -540. 
19. Sungur, Metin, Cemsit Karakurt, Nazan Ozbarlas, and Osman Baspi[INVESTIGATOR_278798]. "Closure of patent ductus 
arteriosus in children, small infants, and premature babies with Amplatzer duct o ccluder II additional 
sizes: multicenter study."Catheterization and Cardiovascular Interventions  82, no. 2 (2013): 245 -252. 
20. Bruckheimer, Elchanan, Max Godfrey, Tamir Dagan, Michael Levinzon, Gabriel Amir, and Einat Birk. "The 
Amplatzer duct occluder II add itional sizes device for transcatheter PDA closure: Initial 
experience."  Catheterization and Cardiovascular Interventions  83, no. 7 (2014): 1097 -1101.  
21. Baspi[INVESTIGATOR_278798], Osman, Derya Aydin Sahin, Ayse Sulu, Ahmet Irdem, Gokhan Gokaslan, Ercan Sivasli, and 
Metin Kil inc. "Transcatheter Closure of Patent Ductus Arteriosus in Under 6 kg and Premature 
Infants."  Journal of interventional cardiology  28, no. 2 (2015): 180 -189.  
 Study Document No: SJM-CIP-[ZIP_CODE]  Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page 45 of 51 
Appendix E: American Heart Association Recommendations for Prophylaxis  
 

 Study Document No: SJM-CIP-[ZIP_CODE]  Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page 46 of 51 
 

 Study Document No: SJM-CIP-[ZIP_CODE]  Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page 47 of 51 
Appendix F: Transthoracic Echocardiography (TTE) Protocol  
The following guidelines should be followed when performing the baseline and follow -up trans -thoracic 
echocardiogram studies. The baseline echocardiogram is used to assess the status of PDA (dimensions and 
flow), along with left ventricular function and dimension measurements. The intra -procedural echocardiogram 
is used to confirm eligibility for the study and to guide the implant procedure.  
 
Machine settings:   Due to the several different types of equipment use d for this test, gain setting must be 
adjusted to guarantee uniformity and quality imaging. The following guidelines should be followed for 
machine setup.  
 
• The echocardiographic machine digital acquisition protocol should be set at a minimum of 3 complete 
acquisition loops gated to the QRS complex (5 loops is the preferred setting). Please make sure these 
settings are changed in the echocardiogram machine “preferences ” prior to starting the imaging protocol, 
and maintained throughout the study. In order for  any ultrasound machine to perform these digital loops, 
ECG pads must be placed and hooked from the subject to the echo machine during the entire image 
acquisition session.  
• Please ensure that both the image frequency is optimized and that the 2 -D and color  Doppler gains are 
properly set so that image quality is maximized.  
• Color Doppler echocardiogram will be represented as “red towards and blue away ” from the transducer. 
Variance or “turbulence ” mappi[INVESTIGATOR_294224].  
• It is best practi ce to test the settings by [CONTACT_294265] “pi[INVESTIGATOR_294225] ” (indicating excessive gain), then the knob should be 
dialed back until just below the point where the pi[INVESTIGATOR_294226] n is eliminated and left at this level for the 
remainder of the imaging study.  
• Sensitivity to low velocity shunts will be maximized by [CONTACT_294266]. This will be done in a stepwise techniq ue while recording on videotape or CD 
in sequential fashion using digital clip storage media. Color flow gain will be adjusted at each step to 
maximize color saturation without overwriting tissue by [CONTACT_294267].  
 
Imaging guidance:  The following guideline should be followed for assessing the PDA status, left ventricular 
function and dimensions, pulmonary and aortic flow and dimensions, and pulmonic and tricuspid valve 
regurgitation.  
 
• The Doppler Echocardiographic transducer orientation will align the ultrasound beam with the blood flow.  
• Doppler echocardiogram should be a complete assessment and reviewed closely in the parasternal short 
axis and parasternal long axis “ductus cut” and in the suprasternal views to interrogate the main 
pulmonary artery  for flow through the PDA and also to the Doppler “pulsed, continuous wave and color” 
for any evidence of obstruction to the left pulmonary artery and descending aorta.  
• Evidence of any residual shunting will be quantified by [CONTACT_294268] (device), along with an assessment of PDA shunt grade using the following 
definitions:  
o Grade 0 —none;  
o Grade 1 —trivial (narrow jet adjacent to the device via the PDA).  Note: the presence of flow via 
existing or newly  formed aortopulmonary collaterals should not be considered as representing a 
shunt via the PDA [see references].  
o Grade 2 —mild (broader jet filling proximal left pulmonary artery branch and extending to main 
pulmonary artery);  
 Study Document No: SJM-CIP-[ZIP_CODE]  Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page 48 of 51 
o Grade 3/4 —moderate to severe (wide jet filling the main pulmonary artery and extending to 
pulmonary valve or distal pulmonary artery branches, which also may be accompanied with the 
presence of flow reversal in the abdominal aortic Doppler pattern during diastole)  
 
Imaging measurements & assessments:  
Baseline:  
2D Imaging  
• Minimal ductal diameter (mm)  
• Maximal ductal diameter (mm)  
• Ductal length (mm)  
• Diameter of aortic isthmus (mm)  
• Diameter of aorta at diaphragm level (mm)  
• Diameter of proximal left pulmonary artery (mm)  
• LV end-diastolic area (parasternal short axis image) (mm2) 
• LV end -systolic area (parasternal short axis image) (mm2) 
• LV api[INVESTIGATOR_294227] (mm)  
• LV api[INVESTIGATOR_294228] (mm)  
• Left ventricular ejection fraction (%)  
• Left ventricular shortening fraction  (%) 
 
Spectral Doppler  
• Peak gradient in descending aorta at the isthmus (mmHg)  
• Mean gradient in descending aorta at the isthmus (mmHg)  
• Doppler pattern in abdominal  aorta  
o Blunted profile with diminished upstroke (Y/N)  
o Holodiastolic antegrade flow (Y/N)  
o Flow reversal during diastole (Y/N)  
• Peak gradient in PDA (mmHg)  
• Peak gradient in left pulmonary artery (mmHg)  
• Mean gradient in left pulmonary artery (mmHg)  
 
Color Doppler  
• Right -to-Left ductal shunting (Y/N)  
• Left-to-Right ductal shunting (Y/N)  
• Tricuspid regurgitation grade (None, Trace, Mild, Moderate, Severe)  
• Pulmonary regurgitation grade (None, Trace, Mild, Moderate, Severe)  
• Aortopulmonary collaterals (Y/N)  
 
Procedure:  
2D Imaging  
• Minimal ductal diameter (mm)  
• Maximal ductal diameter (mm)  
• Ductal  length (mm)  
 
  
 Study Document No: SJM-CIP-[ZIP_CODE]  Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page [ADDRESS_358298] -Procedure and Follow -Up: 
2D Imaging  
• Device within PDA (Y/N)  
• Diameter of aortic isthmus (mm)  
• Diameter of aorta at diaphragm level (mm)  
• Diameter of proximal left pulmonary artery (mm)  
• LV end -diastolic area (parasternal short axis image) (mm2) 
• LV end -systolic area (parasternal short axis image) (mm2) 
• LV api[INVESTIGATOR_294227] (mm)  
• LV api[INVESTIGATOR_294228] (mm)  
• Left ventricular ejection fraction (%)  
• Left ventricular shortening fraction (%)  
 
Spectral Doppler  
• Peak gradient in des cending aorta at the isthmus (mmHg)  
• Mean gradient in descending aorta at the isthmus (mmHg)  
• Doppler pattern in abdominal  aorta  
o Blunted profile with diminished upstroke (Y/N)  
o Holodiastolic antegrade flow (Y/N)  
o Flow reversal during diastole (Y/N)  
• Peak gradi ent in left pulmonary artery (mmHg)  
• Mean gradient in left pulmonary artery (mmHg)  
 
Color Doppler  
• PDA residual shunt grade (None(0), Trivial(1), Mild(2), Moderate/Severe(3/4))  
• Tricuspid regurgitation grade (None, Trivial, Mild, Moderate, Severe)  
• Pulmonary r egurgitation grade (None, Trivial, Mild, Moderate, Severe)  
• Aortopulmonary collaterals (Y/N)  
 
Note:  peak gradient refers to “maximal instantaneous gradient” by [CONTACT_51541].  
References:  
1) Lopez, L., Colan, S. D., Frommelt, P. C., Ensing , G. J., Kendall, K., Younoszai, A. K., ... & Geva, T. 
(2010). Recommendations for quantification methods during the performance of a pediatric 
echocardiogram: a report from the Pediatric Measurements Writing Group of the American Society of 
Echocardiograp hy Pediatric and Congenital Heart Disease Council.  Journal of the American Society of 
Echocardiography , 23(5), 465 -495. 
2) Skinner, J. R., & Silove, E. D. (1995). Aortopulmonary collateral arteries mimicking symptomatic ductal 
shunting in a preterm infant.  British heart journal , 74(1), 93 -94. 
3) Acherman, R. J., Siassi, B., Pratti -Madrid, G., Luna, C., Lewis, A. B., Ebrahimi, M., ... & Ramanathan, R. 
(2000). Systemic to pulmonary collaterals in very low birth weight infants: color doppler detection of 
systemic to pulmonary connections during neonatal and early infancy period. Pediatrics, 105(3), 528 -532. 
 
 
  
 Study Document No: SJM-CIP-[ZIP_CODE]  Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page 50 of 51 
Appendix G: Case Report Forms  
 
The approved CRFs will be kept under a separate cover and available upon request for Regulatory or IRB 
submissions.  
  
 Study Document No: SJM-CIP-[ZIP_CODE]  Ver. D 
Study Name: [CONTACT_294269], distributed, disclosed or used without the express 
written consent of Abbott  
  Page 51 of 51 
Appendix H: Template Informed Consent Form  
 
The approved Informed Consent Template will be kept under a separate cover and available upon request for 
Regulatory or IRB submissions.  
 